<?xml version="1.0" encoding="UTF-8" ?> 
<set>
<DOC>
<DOC_ID>[1]</DOC_ID>
>1.NF00132420
PMID:11856887
TI  - Expression pattern and further characterization of <long_form>human <protein>MAGED2</protein></long_form> and
      identification of rodent orthologues.
AB  - In a search for genes involved in X-linked mental retardation we have
      analyzed the expression pattern and genomic structure of <long_form>human <protein>MAGED2</protein></long_form>.
      This gene is a member of a new defined <protein>MAGE-D</protein> cluster in Xp11.2, a hot
      spot for X-linked mental retardation. Rat and mouse orthologues have been
      isolated. In contrast to the genes of the <protein>MAGE-A</protein>, <protein>MAGE- B</protein> and <protein>MAGE-C</protein>
      clusters, <protein>MAGED2</protein> is expressed ubiquitously. High expression was detected
      in specific brain regions and in the interstitium of testes. Five SNPs in
      the coding region of <long_form>human <protein>MAGED2</protein></long_form> were characterized and their allele
      frequencies determined in a German and Turkish population.
</DOC>
<DOC>
<DOC_ID>[2]</DOC_ID>
>2.NF00118002
PMID:12077706
TI  - Mutations in the <protein>cone photoreceptor G-protein alpha-subunit</protein> gene <protein>GNAT2</protein> in
      patients with achromatopsia.
AB  - Achromatopsia is an autosomal recessively inherited visual disorder that
      is present from birth and that features the absence of color
      discrimination. We here report the identification of five independent
      families with achromatopsia that segregate protein-truncation mutations in
      the <protein>GNAT2</protein> gene, located on chromosome 1p13. <protein>GNAT2</protein> encodes the <protein>cone
      photoreceptor-specific alpha-subunit of transducin</protein>, a <protein>G-protein</protein> of the
      phototransduction cascade, which couples to the <protein>visual pigment</protein>(s). Our
      results demonstrate that <protein>GNAT2</protein> is the third gene implicated in
      achromatopsia.
</DOC>
<DOC>
<DOC_ID>[3]</DOC_ID>
>3.NF00118005
PMID:12149458
TI  - Chimeric <long_form>human <protein>CstF-77</protein></long_form>/<long_form>Drosophila <protein>Suppressor of forked proteins</protein></long_form> rescue
      <protein>suppressor of forked</protein> mutant lethality and mRNA 3' end processing in
      Drosophila.
AB  - The <protein>Suppressor of forked [Su(f)] protein</protein> is the Drosophila homologue of
      <protein>CstF-77</protein>, a <protein>subunit of human cleavage stimulation factor (CstF)</protein> that is
      required for the first step of the mRNA 3' end processing reaction in
      vitro. We have addressed directly the role of <protein>su(f)</protein> in the mRNA 3' end
      processing reaction in vivo. We show that <protein>su(f)</protein> is required for the
      cleavage of pre-mRNA during mRNA 3' end formation. Analysis of the
      functional complementation between <protein>Su(f)</protein> and <protein>CstF-77</protein> shows that most of
      the Drosophila protein (85%) can be exchanged for the human protein to
      produce chimeric <protein>CstF-77</protein>/<protein>Su(f) proteins</protein> that rescue lethality and cleavage
      defect during mRNA 3' end formation in <protein>su(f)</protein> mutants. Interestingly, we
      show that a domain in <long_form>human <protein>CstF-77</protein></long_form> is limiting for the rescue and that
      this domain is not able to reproduce protein interactions with the <protein>CstF
      subunits</protein> of Drosophila. We also show that chimeric <protein>CstF-77</protein>/<protein>Su(f) proteins</protein>
      that rescue lethality of <protein>su(f)</protein> mutants cannot restore utilization of a
      regulated poly(A) site in Drosophila. Taken together, these results
      demonstrate that <protein>CstF-77</protein> and <protein>Su(f)</protein> have the same function in mRNA 3' end
      formation in vivo, but that these two proteins are not interchangeable for
      regulation of poly(A) site utilization.
</DOC>
<DOC>
<DOC_ID>[4]</DOC_ID>
>4.NF00106180
PMID:12196012
TI  - Identification of neurite outgrowth promoting sites on the <protein>laminin alpha 3</protein>
      <protein>chain G</protein> domain.
AB  - <protein>Laminins</protein> are expressed in specific tissues and are involved in various
      biological activities including promoting cell adhesion, growth,
      migration, neurite outgrowth, and differentiation. The <protein>laminin alpha3
      chain</protein> is mainly located in the skin and is also expressed in the floor
      plate of the developing neural tube. Previously, we showed that the <long_form>human
      <protein>laminin alpha3 chain</protein></long_form> LG4 module binds to <long_form><protein>syndecan-2</protein>/4</long_form>, a
      <protein>membrane-associated proteoglycan</protein>, and promotes human fibroblast adhesion.
      Here, we have evaluated the neurite outgrowth activity of the <protein>laminin
      alpha3 chain</protein> LG4 and LG5 modules. Three overlapping recombinant proteins,
      which contained LG4 and/or LG5 modules of the <long_form>human <protein>laminin alpha3 chain</protein></long_form>,
      were prepared using a mammalian cell expression system. Two proteins,
      <protein>rec-alpha3LG4-5</protein> and <protein>rec-alpha3LG4</protein>, promoted cell attachment and neurite
      outgrowth of rat pheochromocytoma PC12 cells, but <protein>rec-alpha3LG5</protein> was
      inactive. Twenty-two peptides covering the entire LG4 module were
      synthesized and tested for cell attachment and neurite outgrowth activity
      to identify active sites of the LG4 module. A3G75 (KNSFMALYLSKG, alpha3
      chain 1411-1422) and A3G83 (GNSTISIRAPVY, alpha3 chain 1476-1487) promoted
      PC12 cell attachment and neurite outgrowth. Additionally, A3G75 and A3G83
      inhibited PC12 cell attachment to <protein>rec-alpha3LG4</protein>. These results suggest
      that the A3G75 and A3G83 sites are important for PC12 cell attachment and
      neurite outgrowth in the <protein>laminin alpha3 chain</protein> LG4 module. We also
      conjugated the A3G75 and A3G83 peptides on chitosan membranes to test
      their potential as bio-materials. These peptide-conjugated chitosan
      membranes were more active for neurite outgrowth than the peptide-coated
      plates. These results suggest that the A3G75- and A3G83-conjugated
      chitosan membranes are applicable as bio-medical materials for neural
      tissue repair and engineering.
</DOC>
<DOC>
<DOC_ID>[5]</DOC_ID>
>5.NF00133153
PMID:12067979
TI  - Aberrant methylation of the <protein>CDH13</protein> (<protein>H-cadherin</protein>) promoter region in
      colorectal cancers and adenomas.
AB  - Expression of the <protein>cadherin</protein> family member <protein>CDH13</protein> (<protein>H-cadherin</protein>) is reduced in
      several human tumors, and it has been hypothesized that this gene
      functions as a <protein>tumor suppressor</protein> gene. Previously, we reported that the 5'
      region of <protein>CDH13</protein> is frequently methylated in breast and lung cancers. Here
      we confirmed the promoter activity of 5' region of <protein>CDH13</protein> by luciferase
      assay and examined its aberrant methylation in colorectal cancers, cell
      lines, and adenomas. Methylation status was investigated by
      methylation-specific PCR (MSP) and by bisulfite DNA sequencing of cloned
      DNA of PCR amplicons. In cell lines, we examined the correlation between
      methylation status and mRNA expression by reverse transcription-PCR.
      Aberrant methylation of <protein>CDH13</protein> was present in 7 of 13 (54%) cell lines, and
      expression was absent in 6 of 13 (46%) cell lines. <protein>CDH13</protein> expression was
      present in six cell lines that showed only the unmethylated form by MSP
      and in one cell line that showed both the methylated and unmethylated
      forms. Treatment with 5-aza-2'-deoxycytidine restored <protein>CDH13</protein> expression in
      methylated cell lines. In surgically resected samples, 17 of 35 (49%)
      cases of primary colorectal cancer, 2 of 33 (6%) cases of corresponding
      nonmalignant colorectal mucosa, and 8 of 19 (42%) adenomas were
      methylated. Sequence data after bisulfite treatment indicated that primary
      cancers and two cell lines with loss of expression were highly methylated
      compared with nonmalignant colorectal epithelial cells, especially at the
      attachment sites of primers for MSP, although there was heterogeneity in
      methylation status. Our results suggest that <protein>CDH13</protein> expression is
      frequently silenced by aberrant methylation in colorectal cancers and
      adenomas and that methylation of <protein>CDH13</protein> commences at an early stage of
      multistep colorectal tumorigenesis.
</DOC>
<DOC>
<DOC_ID>[6]</DOC_ID>
>6.NF00106425
PMID:11836625
TI  - <protein>RFX-B</protein>, a <protein>MHC class II transcription factor</protein>, suppressed in human colorectal
      adenocarcinomas.
AB  - <protein>Regulatory factor X (RFX)</protein> is an essential <protein>MHC class II transcription
      factor</protein> and contains three distinct subunits of which <protein>RFX-B</protein> is one.
      Aberrant expression of <protein>MHC class II</protein> genes is associated with autoimmunity,
      tumour growth and failure to mount an immune response. <protein>RFX-B protein</protein>
      expression in human colorectal adenocarcinomas and in normal adjacent
      tissue was analysed in this study. Western blot analysis showed a
      suppression of <protein>nuclear RFX-B protein</protein> in the tumour tissue.
      Immunohistochemistry revealed that the <protein>RFX-B protein</protein> levels in macrophages
      were generally lower in colorectal cancerous tissue compared to adjacent
      non-cancerous tissue and that focally and not frequently tumour and normal
      epithelial cells were stained weakly for <protein>RFX-B</protein>. As the expression of <protein>MHC
      class II</protein> correlates with the intensity of the immune response system these
      results may support the idea that cancer is associated with
      immunodeficiency and that low levels of <protein>RFX-B</protein> in interstitial macrophages
      could partly explain this thesis.
</DOC>
<DOC>
<DOC_ID>[7]</DOC_ID>
>7.NF00123516
PMID:12037021
TI  - Mutation analysis of the <protein>PIG-A</protein> gene in Korean patients with paroxysmal
      nocturnal haemoglobinuria.
AB  - AIM: Paroxysmal nocturnal haemoglobinuria (PNH) is caused by deficient
      biosynthesis of the glycosylphosphatidylinositol (GPI) anchor in
      haemopoietic stem cells. Mutation of the <protein>phosphatidylinositol glycan class
      A (PIG-A)</protein> gene, an X linked gene that participates in the first step of
      GPI anchor biosynthesis, is responsible for PNH. The characteristics of
      somatic mutation of the <protein>PIG-A</protein> gene in Korean patients with PNH were
      studied. METHODS: Twenty four patients with PNH were selected. Ham tests
      and sucrose haemolysis tests were carried out on all patients. The
      expression of <protein>CD59</protein> in erythrocytes and granulocytes was investigated in 14
      and five patients, respectively, to confirm the diagnosis. Dideoxy
      fingerprinting (ddF) was used to screen mutations, and direct sequencing
      of DNA was performed to characterise the mutations. RESULTS: Gene mutation
      was detected in 12 of the 24 patients. The other 12 patients were negative
      in ddF screening. Ten new mutations and two known mutations were detected.
      The mutations consisted of five deletions, six substitutions, and one
      insertion. These mutations resulted in six premature terminations, three
      abnormal splicings, one missense mutation in exon 2, and two nonsense
      mutations. Two patients with venous thrombosis showed mutations in exon 3
      only. Substitution mutations were seen in six patients and frameshift
      mutations in the other six. CONCLUSIONS: There were 10 new mutations among
      the 12 mutations in the Korean patients with PNH and the characteristics
      of the mutations varied, with no significant hot spots in sites or types.
</DOC>
<DOC>
<DOC_ID>[8]</DOC_ID>
>8.NF00013762
PMID:12223399
TI  - <long_form><protein>COP9 signalosome subunits 4</protein> and 5</long_form> regulate multiple pleiotropic pathways
      in Drosophila melanogaster.
AB  - The <protein>COP9 signalosome (CSN)</protein> is an essential eight-subunit repressor of
      light-regulated development in ARABIDOPSIS: This complex has also been
      identified in animals, though its developmental role remains obscure. <protein>CSN
      subunits</protein> have been implicated in various cellular processes, suggesting a
      possible role for the <protein>CSN</protein> as an integrator of multiple signaling pathways.
      In order to elucidate the function of the <protein>CSN</protein> in animals, a Drosophila
      model system has previously been established. Gel-filtration analysis with
      antibodies against <long_form><protein>CSN subunits 4</protein>, 5 and 7</long_form> revealed that these proteins
      act as a complex in Drosophila that is similar in size to the plant and
      mammalian complexes. Null mutations in either one of two subunits, <protein>CSN4</protein> or
      <protein>CSN5</protein>, are larval lethal. Successful embryogenesis appears to be a
      consequence of maternal contribution of the complex. Biochemical analysis
      indicates that the different subunits are found in both <protein>CSN</protein>-dependent and
      <protein>CSN</protein>-independent forms, and that these forms are differentially affected by
      the mutations. Phenotypic characterization of these two mutants indicates
      that they show both shared and unique phenotypes, which suggest specific
      roles for each subunit. Both mutants have defective oocyte and embryo
      patterning, and defects in response to DNA damage, while <protein>csn5</protein> mutants
      develop melanotic tumors and <protein>csn4</protein> mutants have phenotypes reminiscent of
      defects in ecdysone signaling.
</DOC>
<DOC>
<DOC_ID>[9]</DOC_ID>
>9.NF00124085
PMID:11926999
TI  - Identification of a domain conferring nucleotide binding to the
      <protein>N-acetyl-d-glucosamine 2-epimerase</protein> (<protein>Renin binding protein</protein>).
AB  - <protein>Renin binding protein (RnBP)</protein>, a <protein>cellular renin inhibitor</protein>, has been
      identified as the enzyme <protein>N-acetyl-D-glucosamine (GlcNAc) 2-epimerase</protein>. Our
      recent studies demonstrated that <long_form>rat <protein>GlcNAc 2-epimerase</protein></long_form> has a ten-times
      higher affinity for ATP, dATP, and ddATP than the human enzyme [Takahashi,
      S. et al. (2001) J. Biochem. 130, 815-821]. To identify the domain
      conferring nucleotide binding to <protein>GlcNAc 2-epimerase</protein>, we constructed a
      series of chimeric enzymes successively replacing the three domains of the
      human enzyme (N-terminal, middle, and C-terminal domains) with the
      corresponding domains of the rat enzyme. Chimeras were expressed in
      Escherichia coli JM109 cells under the control of the Taq promoter. The
      purified chimeric enzymes had <protein>GlcNAc 2-epimerase</protein> activity and inhibited
      <protein>renin</protein> activity in a dose-dependent manner. The recombinant human and rat
      enzymes required catalytic amounts of ATP with apparent K(m) values of 73
      and 5.5 microM, respectively. Chimeric enzymes of HHR, RHH, and RHR (H,
      human type domain; R, rat type domain) had nearly the same nucleotide
      specificity as the <long_form>human <protein>GlcNAc 2-epimerase</protein></long_form>. On the other hand, HRR, HRH,
      and RRH chimeras had the same nucleotide specificity as the rat enzyme.
      These results indicate that the middle domain of the <protein>GlcNAc 2-epimerase</protein>
      molecule participates in the specificity for and binding of nucleotides,
      and that nucleotides are essential to form the catalytic domain of the
      enzyme.
</DOC>
<DOC>
<DOC_ID>[10]</DOC_ID>
>10.NF00132428
PMID:12409310
TI  - <protein>alpha 1-Adrenergic receptor subtypes</protein> differentially control the cell cycle
      of transfected CHO cells through a cAMP-dependent mechanism involving
      <protein>p27Kip1</protein>.
AB  - Three distinct <protein>subtypes of alpha(1)-adrenergic receptors</protein> (<long_form>alpha(1)A-,
      alpha(1)B-, and <protein>alpha(1)D-AR</protein></long_form>) play a prominent role in cell growth.
      However, little is known about subtype-specific effects on cell
      proliferation. The activation of <long_form>alpha(1)A- or <protein>alpha(1)B-AR</protein></long_form> inhibits
      serum-promoted cell proliferation, whereas <protein>alpha(1)D-AR</protein> activation does
      not show such an inhibitory effect. Notably, cell-cycle progression was
      blocked at G(1)/S transition after activation of <long_form>alpha(1)A/<protein>alpha(1)B-AR</protein></long_form>
      but not of <protein>alpha(1)D-AR</protein>. In agreement with the differential cell
      proliferation effect, cAMP production was increased after activation of
      <long_form>alpha(1)A/<protein>alpha(1)B-AR</protein></long_form> but not <protein>alpha(1)D-AR</protein>, whereas all <protein>alpha(1)-AR
      subtypes</protein> are associated with inositol 1,4,5-trisphosphate production and
      <protein>mitogen-activated protein kinase</protein> activation in a similar fashion.
      Furthermore, the serum-induced reduction in the levels of the
      <protein>cyclin-dependent kinase inhibitor</protein>, <protein>p27(Kip1)</protein>, was blocked after activation
      of <long_form>alpha(1)A/<protein>alpha(1)B-AR</protein></long_form> but not <protein>alpha(1)D-AR</protein>. These results show that
      <protein>alpha(1)-AR subtypes</protein> differentially activate the cAMP/<protein>p27(Kip1)</protein> pathway
      and thereby have differential inhibitory effects on cell proliferation.
      Subtype-dependent effects should be taken into consideration when
      assessing the physiological response of native cells where <protein>alpha(1)-AR
      subtypes</protein> are generally co-expressed.
</DOC>
<DOC>
<DOC_ID>[11]</DOC_ID>
>11.NF00088410
PMID:12060656
<protein>TI</protein>  - Distinct sets of adjacent <long_form><protein>heterogeneous nuclear ribonucleoprotein (hnRNP)
      A1</protein>/A2</long_form> binding sites control 5' splice site selection in the <protein>hnRNP A1</protein> mRNA
      precursor.
AB  - In the <protein>heterogeneous nuclear ribonucleoprotein (hnRNP) A1</protein> pre-mRNA,
      different regions in the introns flanking alternative exon 7B have been
      implicated in the production of the A1 and A1B mRNA splice isoforms. Among
      these, the CE1a and CE4 elements, located downstream of common exon 7 and
      alternative exon 7B, respectively, are bound by <protein>hnRNP A1</protein> to promote
      skipping of exon 7B in vivo and distal 5' splice site selection in vitro.
      Here, we report that CE1a is flanked by an additional high affinity A1
      binding site (CE1d). In a manner similar to CE1a, CE1d affects 5' splice
      site selection in vitro. Consistent with a role for <protein>hnRNP A1</protein> in the
      activity of CE1d, a mutation that abrogates A1 binding abolishes distal 5'
      splice site activation. Moreover, the ability of CE1d to stimulate distal
      5' splice site usage is lost in an HeLa extract depleted of <protein>hnRNP A/B</protein>
      <protein>proteins</protein>, and the addition of recombinant A1 restores the activity of
      CE1d. Notably, distal 5' splice site selection mediated by A1 binding
      sites is not compromised in an extract prepared from mouse cells that are
      severely deficient in <protein>hnRNP A1 proteins</protein>. In this case, we show that <protein>hnRNP
      A2</protein> compensates for the A1 deficiency. Further studies with the CE4 element
      reveal that it also consists of two distinct portions (CE4m and CE4p),
      each one capable of promoting distal 5' splice site use in an <protein>hnRNP
      A1</protein>-dependent manner. The presence of multiple A1/A2 binding sites
      downstream of common exon 7 and alternative exon 7B probably plays an
      important role in maximizing the activity of <long_form><protein>hnRNP A1</protein>/A2 proteins</long_form>.
</DOC>
<DOC>
<DOC_ID>[12]</DOC_ID>
>12.NF00106186
PMID:11884632
TI  - <protein>Human Rad54B</protein> is a <protein>double-stranded DNA-dependent ATPase</protein> and has biochemical
      properties different from its structural homolog in yeast, <protein>Tid1</protein>/<protein>Rdh54</protein>.
AB  - The <protein>RAD52</protein> epistasis group genes are involved in homologous recombination,
      and they are conserved from yeast to humans. We have cloned a novel human
      gene, <protein>RAD54B</protein>, which is homologous to yeast and <protein>human RAD54</protein>. <protein>Human Rad54B
      (hRad54B)</protein> shares high homology with <protein>human Rad54 (hRad54)</protein> in the central
      region containing the <protein>helicase</protein> motifs characteristic of the <protein>SNF2</protein>/<protein>SWI2</protein>
      family of proteins, but the N-terminal domain is less conserved. In yeast,
      another <protein>RAD54</protein> homolog, <protein>TID1</protein>/<protein>RDH54</protein>, plays a role in recombination.
      <protein>Tid1</protein>/<protein>Rdh54</protein> interacts with yeast <protein>Rad51</protein> and a <protein>meiosis-specific Rad51</protein>
      homolog, <protein>Dmc1</protein>. The N-terminal domain of <protein>hRad54B</protein> shares homology with that
      of <protein>Tid1</protein>/<protein>Rdh54</protein>, suggesting that <protein>Rad54B</protein> may be the human counterpart of
      <protein>Tid1</protein>/<protein>Rdh54</protein>. We purified the <protein>hRad54</protein> and <protein>hRad54B proteins</protein> from
      baculovirus-infected insect cells and examined their biochemical
      properties. <protein>hRad54B</protein>, like <protein>hRad54</protein>, is a <protein>DNA-binding protein</protein> and hydrolyzes
      ATP in the presence of double-stranded DNA, though its rate of ATP
      hydrolysis is lower than that of <protein>hRad54</protein>. <long_form>Human <protein>Rad51</protein></long_form> interacts with <protein>hRad54</protein>
      and enhances its <protein>ATPase</protein> activity. In contrast, neither <long_form>human <protein>Rad51</protein></long_form> nor
      <protein>Dmc1</protein> directly interacts with <protein>hRad54B</protein>. Although <protein>hRad54B</protein> is the putative
      counterpart of <protein>Tid1</protein>/<protein>Rdh54</protein>, our findings suggest that <protein>hRad54B</protein> behaves
      differently from <protein>Tid1</protein>/<protein>Rdh54</protein>.
</DOC>
<DOC>
<DOC_ID>[13]</DOC_ID>
>13.NF00113477
PMID:12044248
TI  - Significance of the <protein>parkin</protein> gene and protein in understanding Parkinson's
      disease.
AB  - Mutations in the <protein>parkin</protein> gene cause autosomal recessive inherited juvenile
      parkinsonism (ARJP) and account for the majority of cases of inherited
      Parkinson's disease (PD) of young onset (&lt;45 years of age). Patients with
      <protein>parkin</protein> mutations commonly have atypical clinical features such as dystonia
      at onset, hyper-reflexia, diurnal fluctuations, and sleep benefit;
      however, <protein>parkin</protein> mutation patients with both typical PD symptoms and older
      age of onset have been identified. <protein>Parkin</protein> is a <protein>ubiquitin protein ligase
      (E3)</protein>, a component in the pathway that attaches <protein>ubiquitin</protein> to specific
      proteins, designating them for degradation by the <protein>proteasome</protein>. Several
      substrates for <protein>parkin</protein> have been identified (<protein>CDCrel-1, o-glycosylated
      alpha-synuclein</protein>, <protein>parkin associated endothelin-like cell receptor</protein>, and
      <protein>synphilin</protein>). The role of these substrates in the pathogenesis of ARJP is
      under active study. Most patients with <protein>parkin</protein> mutations lack Lewy bodies,
      suggesting that functional <protein>parkin</protein> is involved in the formation of these
      highly ubiquitinated inclusions. Furthermore, the recognition that <protein>parkin</protein>
      mutations can lead to a disorder clinically similar to sporadic PD, but
      presumably lacking Lewy bodies, calls into question the necessity of Lewy
      bodies for the diagnosis of PD and nigral cell death. Studies of <protein>parkin</protein>
      are increasing the focus on the role of the <protein>ubiquitin-proteasome system</protein> in
      the pathogenesis of both familial and sporadic PD.
</DOC>
<DOC>
<DOC_ID>[14]</DOC_ID>
>14.NF00101975
PMID:12027902
TI  - Interaction between <protein>p21-activated protein kinase</protein> and <protein>Rac</protein> during
      differentiation of HL-60 human promyelocytic leukemia cell induced by
      all-trans-retinoic acid.
AB  - Undifferentiated human promyelocytic leukemia HL-60 cells show little or
      no superoxide production, but generate a very low O(2)(-) concentration
      upon incubation with all-trans-retinoic acid (ATRA). Its production
      reaches a maximum within 20 h, and thereafter is maintained at an almost
      constant level. The differentiated cells show phorbol 12-myristate
      13-acetate (PMA)-stimulated <protein>NADPH oxidase</protein> activity consistent with the
      amount of <protein>gp91phox</protein> (<protein>phagocytic oxidase</protein>) expressed in the plasma membrane.
      Three <protein>isoforms of p21-activated serine/threonine kinases</protein>, <protein>PAK68</protein>, <protein>PAK65</protein> and
      <protein>PAK62</protein>, were found in both cytosolic and membrane fractions, and their
      contents were significantly increased during induced differentiation. The
      amount of <protein>Rac</protein> identified in the two fractions was also markedly enhanced
      by ATRA- induced differentiation. In contrast, neither <protein>PAK</protein> nor <protein>Rac</protein> was
      seen in the plasma membrane of undifferentiated HL-60 or human neutrophil,
      but they were abundant in the cytoplasmic fraction. Binding of <protein>Rac</protein> with
      <protein>PAK isoforms</protein> was shown in the membrane upon induced differentiation of
      HL-60 cells. Direct binding of purified <protein>Rac1</protein> to <protein>PAK68</protein> was quantified using
      a fluorescent analog of GTP (methylanthraniloyl
      guanosine-5'-[beta,gamma-imido]triphosphate) bound to <protein>Rac</protein> as a reporter
      group. <protein>Rac1</protein> bound to <protein>PAK68</protein> with a 1 : 1 stoichiometry and with a K(d)
      value of 6.7 nm.
</DOC>
<DOC>
<DOC_ID>[15]</DOC_ID>
>15.NF01014359
PMID:12244172
TI  - Evidence for involvement of a hydrophobic patch in framework region 1 of
      <long_form>human <protein>V4-34-encoded Igs</protein></long_form> in recognition of the red blood cell I antigen.
AB  - The <protein>monoclonal IgM cold agglutinins</protein> that bind to the I/i carbohydrate Ags
      on the surface of RBCs all have <protein>Ig H chains</protein> encoded by the <protein>V4-34</protein> gene
      segment. This mandatory use indicates that distinctive amino acid
      sequences may be involved in recognition. Critical amino acids exist in
      framework region 1 (FR1) of <protein>V4-34-encoded Ig</protein>, and these generate a
      specific Id determinant which apparently lies close to the I binding site.
      However, I binding by Id-expressing Ig can be modulated by sequences in
      complementarity-determining region (CDR)(H)3. Examination of the crystal
      structure of an <protein>anti-I cold agglutinin</protein> has revealed a hydrophobic patch in
      FR1 involving residue W7 on beta-strand A and the AVY motif (residues
      23-25) on beta-strand B. In this study we used mutagenesis to show that
      each of the strand components of the hydrophobic patch is required for
      binding the I carbohydrate Ag. In addition, the crystal structure reveals
      that amino acids in the carboxyl-terminal region of CDR(H)3 form a surface
      region adjacent to the hydrophobic patch. We propose that the I
      carbohydrate Ag interacts simultaneously with the entire hydrophobic patch
      in FR1 and with the outside surface of CDR(H)3. This interaction could
      leave most of the conventional binding site available for binding other
      Ags.
</DOC>
<DOC>
<DOC_ID>[16]</DOC_ID>
>16.NF00089060
PMID:11743730
TI  - Solution structures of the <protein>YAP65</protein> WW domain and the variant L30 K in
      complex with the peptides GTPPPPYTVG, N-(n-octyl)-GPPPY and PLPPY and the
      application of peptide libraries reveal a minimal binding epitope.
AB  - The single mutation L30 K in the <protein>Hu-Yap65</protein> WW domain increased the
      stability of the complex with the peptide GTPPPPYTVG (K(d)=40(+/-5)
      microM). Here we report the refined solution structure of this complex by
      NMR spectroscopy and further derived structure-activity relationships by
      using ligand peptide libraries with truncated sequences and a substitution
      analysis that yielded acetyl-PPPPY as the smallest high-affinity binding
      peptide (K(d)=60 microM). The structures of two new complexes with weaker
      binding ligands chosen based on these results (N-(n-octyl)-GPPPYNH(2) and
      Ac-PLPPY) comprising the wild-type WW domain of <protein>Hu-Yap65</protein> were determined.
      Comparison of the structures of the three complexes were useful for
      identifying the molecular basis of high-affinity: hydrophobic and specific
      interactions between the side-chains of Y28 and W39 and P5' and P4',
      respectively, and hydrogen bonds between T37 (donnor) and P5' (acceptor)
      and between W39 (donnor) and T2' (acceptor) stabilize the complex.The
      structure of the complex L30 K <protein>Hu-Yap65</protein> WW domain/GTPPPPYTVG is compared
      to the published crystal structure of the <protein>dystrophin</protein> WW domain bound to a
      segment of the <protein>beta-dystroglycan protein</protein> and to the solution structure of
      the first <protein>Nedd4</protein> WW domain and its prolin-rich ligand, suggesting that WW
      sequences bind proline-rich peptides in an evolutionary conserved fashion.
      The position equivalent to T22 in the <protein>Hu-Yap65</protein> WW domain sequence is seen
      as responsible for differentiation in the binding mode among the WW
      domains of group I.
</DOC>
<DOC>
<DOC_ID>[17]</DOC_ID>
>17.NF00114287
PMID:12606567
TI  - Attenuation of cell adhesion in lymphocytes is regulated by <protein>CYTIP</protein>, a
      protein which mediates signal complex sequestration.
AB  - An important theme in molecular cell biology is the regulation of protein
      recruitment to the plasma membrane. Fundamental biological processes such
      as proliferation, differentiation or leukocyte functions are initiated and
      controlled through the reversible binding of <protein>signaling proteins</protein> to
      phosphorylated membrane components. This is mediated by specialized
      interaction modules, such as SH2 and PH domains. <protein>Cytohesin-1</protein> is an
      <protein>intracellular guanine nucleotide exchange factor</protein>, which regulates
      leukocyte adhesion. The activity of <protein>cytohesin-1</protein> is controlled by phospho
      inositide-dependent membrane recruitment. An <protein>interacting protein</protein> was
      identified, the expression of which is upregulated by <protein>cytokines</protein> in
      hematopoietic cells. This molecule, <protein>CYTIP</protein>, is also recruited to the cell
      cortex by <protein>integrin</protein> signaling via its PDZ domain. However, stimulation of
      Jurkat cells with phorbol ester results in re-localization of <protein>CYTIP</protein> to the
      cytoplasm, and membrane detachment of <protein>cytohesin-1</protein> strictly requires
      co-expression of <protein>CYTIP</protein>. Consequently, stimulated adhesion of Jurkat cells
      to <protein>intracellular adhesion molecule-1</protein> is repressed by <protein>CYTIP</protein>. These findings
      outline a novel mechanism of signal chain abrogation through sequestration
      of a limiting component by specific protein-protein interactions.
</DOC>
<DOC>
<DOC_ID>[18]</DOC_ID>
>18.NF00102867
PMID:12198491
TI  - <protein>Lon protease</protein> preferentially degrades <protein>oxidized mitochondrial aconitase</protein> by
      an ATP-stimulated mechanism.
AB  - <protein>Mitochondrial aconitase</protein> is sensitive to oxidative inactivation and can
      aggregate and accumulate in many age-related disorders. Here we report
      that <protein>Lon protease</protein>, an <protein>ATP-stimulated mitochondrial matrix protein</protein>,
      selectively recognizes and degrades the <protein>oxidized, hydrophobic form of
      aconitase</protein> after mild oxidative modification, but that severe oxidation
      results in <protein>aconitase</protein> aggregation, which makes it a poor substrate for <protein>Lon</protein>.
      Similarly, a morpholino oligodeoxynucleotide directed against the <protein>lon</protein> gene
      markedly decreases the amount of <protein>Lon protein</protein>, <protein>Lon</protein> activity and <protein>aconitase</protein>
      degradation in WI-38 VA-13 human lung fibroblasts and causes accumulation
      of oxidatively modified <protein>aconitase</protein>. The <protein>ATP-stimulated Lon protease</protein> may be
      an essential defence against the stress of life in an oxygen environment.
      By recognizing minor oxidative changes to protein structure and rapidly
      degrading the mildly modified protein, <protein>Lon protease</protein> may prevent extensive
      oxidation, aggregation and accumulation of <protein>aconitase</protein>, which could
      otherwise compromise mitochondrial function and cellular viability.
      <protein>Aconitase</protein> is probably only one of many <protein>mitochondrial matrix proteins</protein> that
      are preferentially degraded by <protein>Lon protease</protein> after oxidative modification.
</DOC>
<DOC>
<DOC_ID>[19]</DOC_ID>
>19.NF00078531
PMID:11745043
TI  - Role of <protein>multidrug resistance 3</protein> deficiency in pediatric and adult liver
      disease: one gene for three diseases.
AB  - <protein>Class III multidrug resistance P-glycoproteins</protein>, <protein>mdr2</protein> in mice and <protein>MDR3</protein> in
      humans, are <protein>canalicular phospholipid translocators</protein> involved in biliary
      phospholipid (phosphatidylcholine) excretion. The role of an <protein>MDR3</protein> gene
      defect in liver disease was initially suspected in a subtype of
      progressive familial intrahepatic cholestasis called PFIC3. Several <protein>MDR3</protein>
      mutations have been identified in children with PFIC3 and are associated
      with a low level of phospholipids in bile, leading to a high biliary
      cholesterol saturation index. Mutations leading to a truncated protein are
      associated with an absence of <protein>canalicular MDR3 protein</protein>. The phenotypic
      spectrum of PFIC3 ranges from neonatal cholestasis to cirrhosis in young
      adults. There is now strong evidence that in addition to PFIC3, an <protein>MDR3</protein>
      defect can be involved in intrahepatic cholestasis of pregnancy and in
      cholesterol gallstone disease. Therefore, at least three human liver
      diseases are due to a single gene deficiency. Patients with PFIC3 due to
      <protein>MDR3</protein> deficiency may benefit from ursodeoxycholic acid therapy and could be
      good candidates for cell therapy in the future.
</DOC>
<DOC>
<DOC_ID>[20]</DOC_ID>
>20.NF00089225
PMID:11558822
TI  - Primary congenital glaucoma: three case reports on novel mutations and
      combinations of mutations in the <protein>GLC3A</protein> (<protein>CYP1B1</protein>) gene.
AB  - PURPOSE: To describe three patients with congenital glaucoma homozygous
      and compound heterozygous for different mutations and benign sequence
      variants in the <protein>cytochrome P 450 1B1 (CYP1B1)</protein> gene. METHODS: All patients
      were examined by slit-lamp biomicroscopy, gonioscopy, measurement of the
      cornea and optic disc, ultrasound biometry, and automated static threshold
      perimetry when possible. Direct sequence analysis was performed on DNA
      extracted from peripheral blood from the patients and their parents.
      RESULTS: For patient 1, a newborn boy with buphthalmos and an opaque
      cornea, a novel homozygous C/T transition in codon 355 (CGA&gt;TGA) led to a
      predicted nonsense codon Arg355X truncating the protein by 188 amino
      acids. For patient 2, a 24-year-old man, a compound heterozygous mutation
      1410-1422del/1546-1555dup was found. For patient 3, a 34-year-old man, two
      novel heterozygous missense mutations resulting in an Ala443Gly and a
      Glu229Lys amino acid exchange and five benign sequence variants were
      found. CONCLUSION: Our results confirm the crucial role of <protein>CYP1B1</protein>
      mutations for congenital glaucoma.
</DOC>
<DOC>
<DOC_ID>[21]</DOC_ID>
>21.NF00982620
PMID:12019563
TI  - <protein>Photoreceptor</protein> renewal: a role for <protein>peripherin/rds</protein>.
AB  - Visual transduction begins with the detection of light within the
      <protein>photoreceptor</protein> cell layer of the retina. Within this layer, specialized
      cells, termed rods and cones, contain the proteins responsible for light
      capture and its transduction to nerve impulses. The phototransductive
      proteins reside within an outer segment region that is connected to an
      inner segment by a thin stalk rich in cytoskeletal elements. A unique
      property of the outer segments is the presence of an elaborate
      intracellular membrane system that holds the phototransduction proteins
      and provides the requisite lipid environment. The maintenance of normal
      physiological function requires that these postmitotic cells retain the
      unique structure of the outer segment regions--stacks of membrane saccules
      in the case of rods and a continuous infolding of membrane in the case of
      cones. Both <protein>photoreceptor</protein> rod and cone cells achieve this through a series
      of coordinated steps. As new membranous material is synthesized,
      transported, and incorporated into newly forming outer segment membranes,
      a compensatory shedding of older membranous material occurs, thereby
      maintaining the segment at a constant length. These processes are
      collectively referred to as ROS (rod outer segment) or COS (cone outer
      segment) renewal. We review the cellular and molecular events responsible
      for these renewal processes and present the recent but compelling
      evidence, drawn from molecular genetic, biochemical, and biophysical
      approaches, pointing to an essential role for a unique <protein>tetraspanning
      membrane protein</protein>, called <protein>peripherin/rds</protein>, in the processes of disk
      morphogenesis.
</DOC>
<DOC>
<DOC_ID>[22]</DOC_ID>
>22.NF00095628
PMID:12060708
TI  - A role for <protein>ASIC3</protein> in the modulation of high-intensity pain stimuli.
AB  - <protein>Acid-sensing ion channel 3 (ASIC3)</protein>, a <protein>proton-gated ion channel</protein> of the
      <protein>degenerins/epithelial sodium channel (DEG/ENaC) receptor</protein> family is
      expressed predominantly in sensory neurons including nociceptive neurons
      responding to protons. To study the role of <protein>ASIC3</protein> in pain signaling, we
      generated <protein>ASIC3</protein> knockout mice. Mutant animals were healthy and responded
      normally to most sensory stimuli. However, in behavioral assays for pain
      responses, <protein>ASIC3</protein> null mutant mice displayed a reduced latency to the onset
      of pain responses, or more pain-related behaviors, when stimuli of
      moderate to high intensity were used. This unexpected effect seemed
      independent of the modality of the stimulus and was observed in the acetic
      acid-induced writhing test (0.6 vs. 0.1-0.5%), in the hot-plate test (52.5
      and 55 vs. 50 degrees C), and in tests for mechanically induced pain
      (tail-pinch vs. von Frey filaments). We postulate that <protein>ASIC3</protein> is involved
      in modulating moderate- to high-intensity pain sensation.
</DOC>
<DOC>
<DOC_ID>[23]</DOC_ID>
>23.NF00866395
PMID:11986327
TI  - Cloning and characterization of <long_form>human <protein>Siglec-11</protein></long_form>. A recently evolved
      signaling that can interact with <protein>SHP-1</protein> and <protein>SHP-2</protein> and is expressed by
      tissue macrophages, including brain microglia.
AB  - <protein>Siglecs</protein> are <protein>sialic acid-recognizing animal lectins</protein> of the <protein>immunoglobulin</protein>
      superfamily. We have cloned and characterized a novel human molecule,
      <protein>Siglec-11</protein>, that belongs to the subgroup of <protein>CD33/Siglec-3-related Siglecs</protein>.
      As with others in this subgroup, the cytosolic domain of <protein>Siglec-11</protein> is
      phosphorylated at tyrosine residue(s) upon pervanadate treatment of cells
      and then recruits the <protein>protein-tyrosine phosphatases SHP-1</protein> and <protein>SHP-2</protein>.
      However, <protein>Siglec-11</protein> has several novel features relative to the other
      <protein>CD33/Siglec-3-related Siglecs</protein>. First, it binds specifically to
      alpha2-8-linked sialic acids. Second, unlike other <protein>CD33/Siglec-3-related
      Siglecs</protein>, <protein>Siglec-11</protein> was not found on peripheral blood leukocytes. Instead,
      we observed its expression on macrophages in various tissues, such as
      liver Kupffer cells. Third, it was also expressed on brain microglia, thus
      becoming the second <protein>Siglec</protein> to be found in the nervous system. Fourth,
      whereas the <protein>Siglec-11</protein> gene is on human chromosome 19, it lies outside the
      previously described <protein>CD33/Siglec-3-related Siglec</protein> cluster on this
      chromosome. Fifth, analyses of genome data bases indicate that <protein>Siglec-11</protein>
      has no mouse ortholog and that it is likely to be the last canonical <long_form>human
      <protein>Siglec</protein></long_form> to be reported. Finally, although <protein>Siglec-11</protein> shows marked sequence
      similarity to <long_form>human <protein>Siglec-10</protein></long_form> in its extracellular domain, the cytosolic
      tail appears only distantly related. Analysis of genomic regions
      surrounding the <protein>Siglec-11</protein> gene suggests that it is actually a chimeric
      molecule that arose from relatively recent gene duplication and
      recombination events, involving the extracellular domain of a closely
      related ancestral <protein>Siglec</protein> gene (which subsequently became a pseudogene) and
      a transmembrane and cytosolic tail derived from another ancestral <protein>Siglec</protein>.
</DOC>
<DOC>
<DOC_ID>[24]</DOC_ID>
>24.NF00866396
PMID:11546873
TI  - Role of the <protein>nonsense-mediated decay factor hUpf3</protein> in the splicing-dependent
      exon-exon junction complex.
AB  - Nonsense-mediated messenger RNA (mRNA) decay, or NMD, is a critical
      process of selective degradation of mRNAs that contain premature stop
      codons. NMD depends on both pre-mRNA splicing and translation, and it
      requires recognition of the position of stop codons relative to exon-exon
      junctions. A key factor in NMD is <protein>hUpf3</protein>, a mostly <protein>nuclear protein</protein> that
      shuttles between the nucleus and cytoplasm and interacts specifically with
      spliced mRNAs. We found that <protein>hUpf3</protein> interacts with Y14, a <protein>component of
      post-splicing mRNA-protein (mRNP) complexes</protein>, and that <protein>hUpf3</protein> is enriched in
      <protein>Y14-containing mRNP complexes</protein>. The <protein>mRNA export factors Aly/REF</protein> and <protein>TAP</protein> are
      also associated with <protein>nuclear hUpf3</protein>, indicating that <protein>hUpf3</protein> is in <protein>mRNP
      complexes</protein> that are poised for nuclear export. Like Y14 and <protein>Aly/REF</protein>, <protein>hUpf3</protein>
      binds to spliced mRNAs specifically ( approximately 20 nucleotides)
      upstream of exon-exon junctions. The splicing-dependent binding of <protein>hUpf3</protein>
      to mRNAs before export, as part of the complex that assembles near
      exon-exon junctions, allows it to serve as a link between splicing and NMD
      in the cytoplasm.
</DOC>
<DOC>
<DOC_ID>[25]</DOC_ID>
>25.NF00779079
PMID:11597141
TI  - Cloning and chromosomal localization of a gene encoding a novel
      <protein>serine/threonine kinase</protein> belonging to the subfamily of <protein>testis-specific
      kinases</protein>.
AB  - Using reverse transcription-polymerase chain reaction (RT-PCR) with
      degenerate oligonucleotides corresponding to two highly conserved motifs
      within the <protein>protein kinase</protein> family of catalytic domains, we isolated a PCR
      fragment encoding a novel member of the <protein>testis-specific serine/threonine
      kinases (STK)</protein> from mouse male mixed germ cell mRNA. This PCR fragment
      recognized a 1020-bp transcript in male germ cells by northern blot
      analysis and was used to clone a full-length cDNA from a mouse mixed germ
      cell cDNA library. This cDNA has an open reading frame of 804 bases
      encoding a protein of 268 amino acids. This novel gene is almost identical
      to <protein>Stk22c</protein>, encoding a recently described <protein>testis-specific protein kinase</protein>,
      except for base-pair deletions that result in a shift in the coding region
      and an alteration of 22 amino acids (residues 109-131). Due to its
      homology with <protein>Stk22c</protein>, we have called this <protein>protein kinase</protein> gene <protein>Stk22d</protein>.
      Northern blot analysis revealed that this <protein>protein kinase</protein> is
      developmentally expressed in testicular germ cells and is not present in
      brain, ovary, kidney, liver, or early embryonic cells. We then cloned the
      human homologue of this <protein>protein kinase</protein> gene (<protein>STK22C</protein>) and found it to be
      expressed exclusively in the testis. Fluorescence in situ hybridization
      with both the human and mouse cDNA clones revealed syntenic localization
      on chromosomes 1p34-p35 and 4E1, respectively.
</DOC>
<DOC>
<DOC_ID>[26]</DOC_ID>
>26.NF00142150
PMID:12037680
TI  - CK2-dependent phosphorylation of the <protein>E2 ubiquitin conjugating enzyme UBC3B</protein>
      induces its interaction with <protein>beta-TrCP</protein> and enhances <protein>beta-catenin</protein>
      degradation.
AB  - <protein>Protein kinase CK2</protein> is a ubiquitous and pleiotropic <protein>Ser/Thr protein kinase</protein>
      involved in cell growth and transformation. Here we report the
      identification by yeast interaction trap of a <protein>CK2 interacting protein</protein>,
      <protein>UBC3B</protein>, which is highly homologous to the <protein>E2 ubiquitin conjugating enzyme</protein>
      <protein>UBC3</protein>/<protein>CDC34</protein>. <protein>UBC3B</protein> complements the <long_form>yeast <protein>cdc34-2</protein></long_form> cell cycle arrest mutant
      in S. cerevisiae and transfers <protein>ubiquitin</protein> to a target substrate in vitro.
      <protein>UBC3B</protein> is specifically phosphorylated by <protein>CK2</protein> in vitro and in vivo. We
      mapped by deletions and site directed mutagenesis the phosphorylation site
      to a serine residue within the C-terminal domain in position 233 of <protein>UBC3B</protein>
      and in the corresponding serine residue of <protein>UBC3</protein>. Following <protein>CK2</protein>-dependent
      phosphorylation both <protein>UBC3B</protein> and <protein>UBC3</protein> bind to the <protein>F-box protein beta-TrCP</protein>,
      the substrate recognition <protein>subunit of an SCF (Skp1, Cul1, F-box) ubiquitin
      <protein>ligase</protein></protein>. Furthermore, we observed that co-transfection of <protein>CK2alpha</protein>'
      together with <protein>UBC3B</protein>, but not with <protein>UBC3DeltaC</protein>, enhances the degradation of
      <protein>beta-catenin</protein>. Taken together these data suggest that <protein>CK2</protein>-dependent
      phosphorylation of <protein>UBC3</protein> and <protein>UBC3B</protein> functions by regulating <protein>beta-TrCP</protein>
      substrate recognition.
</DOC>
<DOC>
<DOC_ID>[27]</DOC_ID>
>27.NF00126031
PMID:12239140
TI  - Transgenic overexpression of <protein>human IL-17E</protein> results in eosinophilia,
      B-lymphocyte hyperplasia, and altered antibody production.
AB  - We have identified and cloned a novel <long_form>human <protein>cytokine</protein></long_form> with homology to
      <protein>cytokines</protein> of the <protein>interleukin-17 (IL-17)</protein> family, which we have termed <protein>human
      IL-17E (hIL-17E)</protein>. With the identification of several <protein>IL-17</protein> family members,
      it is critical to understand the in vivo function of these molecules. We
      have generated transgenic mice overexpressing <protein>hIL-17E</protein> using an
      <protein>apolipoprotein E (ApoE)</protein> hepatic promoter. These mice displayed changes in
      the peripheral blood, particularly, a 3-fold increase in total leukocytes
      consisting of increases in eosinophils, lymphocytes, and neutrophils.
      Splenomegaly and lymphoadenopathy were predominant and included marked
      eosinophil infiltrates and lymphoid hyperplasia. <protein>CCR3</protein>(+) eosinophils
      increased in the blood and lymph nodes of the transgenic mice by 50- and
      300-fold, respectively. Eosinophils also increased 8- to 18-fold in the
      bone marrow and spleen, respectively. In the bone marrow, most of the
      eosinophils had an immature appearance. <protein>CD19</protein>(+) B cells increased 2- to
      5-fold in the peripheral blood, 2-fold in the spleen, and 10-fold in the
      lymph nodes of transgenic mice, whereas <protein>CD4</protein>(+) T lymphocytes increased
      2-fold in both blood and spleen. High serum levels of the <protein>cytokines IL-2</protein>,
      <protein>IL-4</protein>, <protein>IL-5</protein>, <protein>granulocyte colony-stimulating factor</protein>, <protein>eotaxin</protein>, and <protein>interferon
      gamma</protein> were observed. Consistent with B-lymphocyte increases, <protein>serum
      immunoglobulin (Ig) M</protein>, <protein>IgG</protein>, and <protein>IgE</protein> were significantly elevated. Antigenic
      challenge of the transgenic mice with <protein>keyhole limpet hemocyanin (KLH)</protein>
      resulted in a decrease in <protein>anti-KLH IgG</protein> accompanied by increases of
      <long_form><protein>anti-KLH IgA</protein> and <protein>IgE</protein></long_form>. In situ hybridization of transgenic tissues revealed
      that <protein>IL-17Rh1</protein> (<protein>IL-17BR</protein>/<protein>Evi27</protein>), a <protein>receptor</protein> that binds <protein>IL-17E</protein>, is
      up-regulated. Taken together, these data indicate that <protein>IL-17E</protein> regulates
      hematopoietic and immune functions, stimulating the development of
      eosinophils and B lymphocytes. The fact that <protein>hIL-17E</protein> overexpression
      results in high levels of circulating eosinophils, <protein>IL-4</protein>, <protein>IL-5</protein>, <protein>eotaxin</protein>,
      and <protein>IgE</protein> suggests that <protein>IL-17E</protein> may be a <protein>proinflammatory cytokine</protein> favoring
      Th2-type immune responses.
</DOC>
<DOC>
<DOC_ID>[28]</DOC_ID>
>28.NF00108133
PMID:12547166
TI  - Altered splicing pattern of <protein>TACC1</protein> mRNA in gastric cancer.
AB  - <protein>Transforming acidic coiled-coil (TACC) proteins</protein> are <protein>centrosome and
      microtubule-associated proteins</protein> that are essential for mitotic spindle
      function. We identified <protein>TACC1</protein> as an <protein>immunogenic protein</protein> and a potential
      <protein>tumor antigen</protein> by applying serological identification of antigens by
      recombinant expression cloning (SEREX) technique to screen a gastric
      cancer cDNA library. The 5'RLM-RACE and reverse transcriptase polymerase
      chain reaction analyses revealed at least six different transcript
      variants of <protein>TACC1</protein> with variable transcription start sites and alternative
      exon usage (designated <long_form><protein>TACC1-A</protein>-<protein>TACC1-F</protein></long_form>). All transcripts differ in their
      5' ends but share an identical 3' region encoding coiled-coil domain. Four
      transcripts were universally expressed in all normal tissues analyzed but
      <protein>TACC1-D</protein> and <protein>TACC1-F</protein> showed a restricted expression pattern. <protein>TACC1-F</protein>, a
      transcript representing the SEREX-identified cDNA clone, was predominantly
      expressed in brain and gastric tumors to a similar level. <protein>TACC1-D</protein> was only
      weakly detectable in kidney and colon but not in other normal tissues,
      while a relatively strong expression was observed in 50% of gastric cancer
      tissue samples analyzed. These transcript variants are generated possibly
      as a result of alterations in efficiency and pattern of alternative
      splicing; these isoforms may represent genetic markers, for example
      <protein>TACC1-D</protein> for gastric cancer. We also propose that inappropriate expression
      of the isoforms in gastric cancer cells might result in dysfunction of
      <protein>TACC1</protein> thus contributing to the genetic instability.
</DOC>
<DOC>
<DOC_ID>[29]</DOC_ID>
>29.NF00131704
PMID:12058028
TI  - The <protein>stress-activated protein kinases p38 alpha</protein> and <protein>JNK1</protein> stabilize
      <protein>p21</protein>(<protein>Cip1</protein>) by phosphorylation.
AB  - Stress signals activate the <protein>SAPK</protein>/<protein>JNK</protein> and <protein>p38 MAPK</protein> classes of <protein>protein
      kinases</protein>, which mediate cellular responses, including steps in apoptosis
      and the maturation of some cell types. We now show that stress signals
      initiated by <protein>transforming growth factor-beta 1 (TGF-beta 1)</protein> induce G(1)
      arrest through protein stabilization of the <protein>CDK inhibitor p21(Cip1)</protein>.
      <protein>TGF-beta 1</protein> was previously shown to increase <protein>p21 protein</protein> levels, which in
      turn mediated G(1) arrest through inactivation of the <long_form><protein>CDK2</protein>-<protein>cyclin E</protein>
      complex</long_form> in HD3 cells (Yan, Z., Kim, G.-Y., Deng, X., and Friedman, E.
      (2002) J. Biol. Chem. 277, 9870-9879). We now demonstrate that the
      increase in <protein>p21</protein> abundance is caused by a post-transcriptional,
      <protein>SMAD</protein>-independent mechanism. <protein>TGF-beta1</protein> activated <protein>p38 alpha</protein> and <protein>JNK1</protein>, which
      initiated the phosphorylation of <protein>p21</protein>. <protein>TGF-beta1</protein> treatment increased the
      half-life of <protein>p21</protein> by 3-4-fold. The increase in <protein>p21</protein> stability was detected
      following activation of <protein>p38 alpha</protein> and <protein>JNK1</protein>, and treatment of cells with
      the <protein>p38</protein> inhibitor SB203580 prevented this increase in <protein>p21</protein> stability. <protein>p38
      alpha</protein> and <protein>JNK1</protein> phosphorylated <protein>p21</protein> in vivo, and both <protein>p38 alpha</protein> and <protein>JNK1</protein>
      phosphorylated <protein>p21</protein> at Ser(130) in vitro. Peptide mapping demonstrated that
      both <protein>TGF-beta 1</protein> and <protein>p38 alpha</protein> induced phosphorylation of <protein>p21</protein> at Ser(130)
      in vivo, and mutation of Ser(130) to alanine rendered <protein>p21</protein> less stable than
      wild-type <protein>p21</protein>. <protein>TGF-beta 1</protein> increased the stability of wild-type <protein>p21</protein>, but
      not the <protein>p21</protein>-S130A mutant. These findings demonstrate that <protein>SAPKs</protein> can
      mediate cell cycle arrest through post-translational modification of <protein>p21</protein>.
</DOC>
<DOC>
<DOC_ID>[30]</DOC_ID>
>30.NF00142154
PMID:12493765
TI  - <protein>Transcriptional repressor germ cell-less (GCL)</protein> and <protein>barrier to
      autointegration factor (BAF)</protein> compete for binding to <protein>emerin</protein> in vitro.
AB  - <protein>Emerin</protein> belongs to the &quot;LEM domain&quot; family of <protein>nuclear proteins</protein>, which
      contain a characteristic approximately 40-residue LEM motif. The LEM
      domain mediates direct binding to <protein>barrier to autointegration factor (BAF)</protein>,
      a <protein>conserved 10-kDa chromatin protein</protein> essential for embryogenesis in
      Caenorhabditis elegans. In mammalian cells, <protein>BAF</protein> recruits <protein>emerin</protein> to
      chromatin during nuclear assembly. <protein>BAF</protein> also mediates chromatin
      decondensation during nuclear assembly. The LEM domain and central region
      of <protein>emerin</protein> are essential for binding to <protein>BAF</protein> and <protein>lamin A</protein>, respectively.
      However, two other conserved regions of <protein>emerin</protein> lacked ascribed functions,
      suggesting that <protein>emerin</protein> could have additional partners. We discovered that
      these &quot;unascribed&quot; domains of <protein>emerin</protein> mediate direct binding to a
      <protein>transcriptional repressor</protein>, <protein>germ cell-less (GCL)</protein>. <protein>GCL</protein> co-immunoprecipitates
      with <protein>emerin</protein> from HeLa cells. We determined the binding affinities of
      <protein>emerin</protein> for <protein>GCL</protein>, <protein>BAF</protein>, and <protein>lamin A</protein> and analyzed their oligomeric
      interactions. We showed that <protein>emerin</protein> forms stable complexes with either
      <protein>lamin A</protein> plus <protein>GCL</protein> or <protein>lamin A</protein> plus <protein>BAF</protein>. Importantly, <protein>BAF</protein> competed with <protein>GCL</protein>
      for binding to <protein>emerin</protein> in vitro, predicting that <protein>emerin</protein> can form at least
      two distinct types of complexes in vivo. Loss of <protein>emerin</protein> causes
      Emery-Dreifuss muscular dystrophy, a tissue-specific inherited disease
      that affects skeletal muscles, major tendons, and the cardiac conduction
      system. Although <protein>GCL</protein> alone cannot explain the disease mechanism, our
      results strongly support gene expression models for Emery-Dreifuss
      muscular dystrophy by showing that <protein>emerin</protein> binds directly to a
      <protein>transcriptional repressor</protein>, <protein>GCL</protein>, and by suggesting that <long_form><protein>emerin</protein>-repressor
      complexes</long_form> might be regulated by <protein>BAF</protein>. Biochemical roles for <protein>emerin</protein> in gene
      expression are discussed.
</DOC>
<DOC>
<DOC_ID>[31]</DOC_ID>
>31.NF00104652
PMID:11896212
TI  - Infantile dilated X-linked cardiomyopathy, <protein>G4.5</protein> mutations, altered lipids,
      and ultrastructural malformations of mitochondria in heart, liver, and
      skeletal muscle.
AB  - Mutations in the Xq28 gene <protein>G4.5</protein> lead to dilated cardiomyopathy (DCM).
      Differential splicing of <protein>G4.5</protein> results in a family of proteins called
      &quot;<protein>tafazzins</protein>&quot; with homology to <protein>acyltransferases</protein>. These enzymes assemble
      fatty acids into membrane lipids. We sequenced <protein>G4.5</protein> in two kindreds with
      X-linked DCM and in two unrelated men, one with idiopathic DCM and the
      other with DCM of arrhythmogenic right ventricular dysplasia. We examined
      the ultrastructure of heart, liver, and muscle biopsy specimens in these
      three DCM types; we used gas chromatography to compare fatty acid
      composition in heart, liver, and muscle autopsy specimens of two patients
      of kindred 1 with that of controls. In X-linked DCM, <protein>G4.5</protein> had a stop codon
      (E188X), a nonsense mutation, in kindred 1 and an amino acid substitution
      (G240R), a missense mutation, in kindred 2. In the two men with isolated
      DCM, <protein>G4.5</protein> was not mutated. Ultrastructural mitochondrial malformations
      were present in the biopsy tissues of the patients with DCM. Cardiac
      biopsy specimens of both kindreds with X-linked DCM exhibited greatly
      enlarged mitochondria with large bundles of stacked, compacted, disarrayed
      cristae that differed from those of the two types of isolated DCM. Autopsy
      tissue of patients with X-linked DCM had decreased unsaturated and
      increased saturated fatty acid concentrations. Seven of 13 published <protein>G4.5</protein>
      missense mutations, including the one presented here, occur in
      <protein>acyltransferase</protein> motifs. Impaired <protein>acyltransferase</protein> function could result in
      increased fatty acid saturation that would decrease membrane fluidity.
      Mitochondrial membrane proliferation may be an attempt to compensate for
      impaired function of <protein>acyltransferase</protein>. Cardiac ultrastructure separates
      X-linked DCM with <protein>G4.5</protein> mutations from the two types of isolated DCM
      without <protein>G4.5</protein> mutations. Electron microscopy of promptly fixed myocardial
      biopsy specimens has a role in defining the differential diagnosis of DCM.
      Mutational analysis of the <protein>G4.5</protein> gene also serves this purpose.
</DOC>
<DOC>
<DOC_ID>[32]</DOC_ID>
>32.NF00107244
PMID:12054652
TI  - <protein>Phospholipase C-beta 2</protein> interacts with <protein>mitogen-activated protein kinase
      <protein>kinase</protein> 3</protein>.
AB  - <protein>Phospholipase C (PLC)-beta enzymes</protein> (<long_form><protein>isoenzymes beta 1</protein>-beta 4</long_form>) are
      activated by <protein>G protein subunits</protein>, leading to the generation of
      intracellular messengers which mobilize calcium and activate <protein>protein
      kinase C</protein>. It has recently been recognized that these enzymes interact with
      and are regulated by proteins other than <protein>G proteins</protein>. Using the yeast
      two-hybrid technique to screen a leukocyte library we identified
      <protein>mitogen-activated protein kinase kinase 3 (MKK3)</protein> as a partner of <protein>PLC-beta
      2</protein>. The interaction was confirmed by co-immunoprecipitation assays which
      indicated that <protein>MKK3</protein> interacts with <protein>PLC-beta 2</protein>, but not with other
      <protein>PLC-betas</protein>. <protein>PLC-beta 2</protein> interacted weakly with <protein>MKK6</protein>, which is related to
      <protein>MKK3</protein>, but not with the other <protein>MKK3</protein> tested. The region of <protein>PLC-beta 2</protein>
      involved in the interaction with <protein>MKK3</protein> was mapped to the C-terminus of
      <protein>PLC-beta 2</protein>. <protein>p38MAPK</protein> also co-immunoprecipitated with <protein>PLC-beta 2</protein>. The data
      suggest that <protein>PLC-beta 2</protein> serves an unappreciated role assembling components
      of the <protein>p38MAPK</protein> signaling module.
</DOC>
<DOC>
<DOC_ID>[33]</DOC_ID>
>33.NF00108136
PMID:12606047
TI  - <protein>Myeloperoxidase</protein>/nitrite-mediated lipid peroxidation of <protein>low-density
      lipoprotein</protein> as modulated by flavonoids.
AB  - In the presence of a H(2)O(2)-generating system, <protein>myeloperoxidase (MPO)</protein>
      caused conjugated diene formation in <protein>low-density lipoprotein (LDL)</protein>,
      indicating lipid peroxidation which was dependent on nitrite but not on
      chloride. The oxidation of <protein>LDL</protein> was inhibited by micromolar concentrations
      of flavonoids such as (-)-epicatechin, quercetin, rutin, taxifolin and
      luteolin, presumably via scavenging of the <protein>MPO</protein>-derived NO(2) radical. The
      flavonoids served as substrates of <protein>MPO</protein> leading to products with distinct
      absorbance spectra. The <protein>MPO</protein>-catalyzed oxidation of flavonoids was
      accelerated in the presence of nitrite.
</DOC>
<DOC>
<DOC_ID>[34]</DOC_ID>
>34.NF00098301
PMID:11925441
TI  - Determinants of the substrate specificity of <protein>multidrug resistance protein
      1</protein>: role of amino acid residues with hydrogen bonding potential in
      predicted transmembrane helix 17.
AB  - <long_form>Human <protein>multidrug resistance protein 1 (MRP1)</protein></long_form> confers resistance to many
      natural product chemotherapeutic agents and actively transports
      structurally diverse organic anion conjugates. We previously demonstrated
      that two hydrogen-bonding amino acid residues in the predicted
      transmembrane 17 (TM17) of <protein>MRP1</protein>, Thr(1242) and Trp(1246), were important
      for drug resistance and 17beta-estradiol 17-(beta-d-glucuronide)
      (E(2)17betaG) transport. To determine whether other residues with hydrogen
      bonding potential within TM17 influence substrate specificity, we replaced
      Ser(1233), Ser(1235), Ser(1237), Gln(1239), Thr(1241), and Asn(1245) with
      Ala and Tyr(1236) and Tyr(1243) with Phe. Mutations S1233A, S1235A,
      S1237A, and Q1239A had no effect on any substrate tested. In contrast,
      mutations Y1236F and T1241A decreased resistance to vincristine but not to
      VP-16, doxorubicin, and epirubicin. Mutation Y1243F reduced resistance to
      all drugs tested by 2-3-fold. Replacement of Asn(1245) with Ala also
      decreased resistance to VP-16, doxorubicin, and epirubicin but increased
      resistance to vincristine. This mutation also decreased E(2)17betaG
      transport approximately 5-fold. Only mutation Y1243F altered the ability
      of <protein>MRP1</protein> to transport both leukotriene 4 and E(2)17betaG. Together with our
      previous results, these findings suggest that residues with side chain
      hydrogen bonding potential, clustered in the cytoplasmic half of TM17,
      participate in the formation of a substrate binding site.
</DOC>
<DOC>
<DOC_ID>[35]</DOC_ID>
>35.NF00122637
PMID:12393902
TI  - <protein>MdmX</protein> is a <protein>RING finger ubiquitin ligase</protein> capable of synergistically
      enhancing <protein>Mdm2</protein> ubiquitination.
AB  - It has been well documented that <protein>Mdm2</protein> and its homologue <protein>MdmX</protein> not only are
      critical negative regulators of the <protein>tumor suppressor p53</protein> but that both
      <protein>Mdm2</protein> and <protein>MdmX</protein> interact to affect the function of the other. The mechanisms
      through which these effects are manifested, however, remain unclear.
      Although <protein>Mdm2</protein> has been established as a <protein>RING finger ubiquitin ligase</protein>, <protein>MdmX</protein>
      has not been shown to possess this activity despite the extensive sequence
      homology between their respective RING finger domains. Here we demonstrate
      that <protein>MdmX</protein> acts as a <protein>ubiquitin ligase</protein> in vitro, being capable of
      autoubiquitination, as well as mediating the ubiquitination of <protein>p53</protein>. The
      addition of <protein>Mdm2</protein> to in vitro ubiquitination assays containing <protein>MdmX</protein> results
      in a synergistic increase of <protein>ubiquitin</protein> conjugation. Analysis of the
      resulting <protein>ubiquitin</protein> conjugates reveals that this observed synergy reflects
      an increase in <protein>Mdm2</protein> ubiquitination. This study also suggests that
      ubiquitination of <protein>Mdm2</protein> and <protein>MdmX</protein> may not serve as a signal for degradation,
      as we show that each are capable of synthesizing non-lysine 48
      <protein>polyubiquitin chains</protein> and, in fact, utilize multiple lysine linkages. Taken
      together, these findings suggest a more active role for <protein>MdmX</protein> in the
      <protein>Mdm2</protein>-<protein>MdmX</protein>-<protein>p53</protein> regulatory network than has been proposed previously.
</DOC>
<DOC>
<DOC_ID>[36]</DOC_ID>
>36.NF00097330
PMID:12006491
TI  - <long_form>Human <protein>SIR2</protein></long_form> deacetylates <protein>p53</protein> and antagonizes <protein>PML</protein>/<protein>p53</protein>-induced cellular
      senescence.
AB  - The <long_form>yeast <protein>Sir2 protein</protein></long_form> mediates chromatin silencing through an intrinsic
      <protein>NAD-dependent histone deacetylase</protein> activity. <protein>Sir2</protein> is a conserved protein
      and was recently shown to regulate lifespan extension both in budding
      yeast and worms. Here, we show that <protein>SIRT1</protein>, the <long_form>human <protein>Sir2</protein></long_form> homolog, is
      recruited to the <protein>promyelocytic leukemia protein (PML)</protein> nuclear bodies of
      mammalian cells upon overexpression of either <protein>PML</protein> or <protein>oncogenic Ras</protein>
      (<protein>Ha-rasV12</protein>). <protein>SIRT1</protein> binds and deacetylates <protein>p53</protein>, a <long_form><protein>component of PML</protein> nuclear
      bodies</long_form>, and it can repress <protein>p53</protein>-mediated transactivation. Moreover, we show
      that <protein>SIRT1</protein> and <protein>p53</protein> co-localize in nuclear bodies upon <protein>PML</protein> upregulation.
      When overexpressed in primary mouse embryo fibroblasts (MEFs), <protein>SIRT1</protein>
      antagonizes <protein>PML</protein>-induced acetylation of <protein>p53</protein> and rescues <protein>PML</protein>-mediated
      premature cellular senescence. Taken together, our data establish the
      <protein>SIRT1 deacetylase</protein> as a novel negative regulator of <protein>p53</protein> function capable of
      modulating cellular senescence.
</DOC>
<DOC>
<DOC_ID>[37]</DOC_ID>
>37.NF00116239
PMID:11856758
TI  - Role of <protein>integrin-linked kinase</protein> in leukocyte recruitment.
AB  - <protein>Chemokines</protein> modulate <protein>leukocyte integrin</protein> avidity to coordinate adhesion and
      subsequent transendothelial migration, although the sequential signaling
      pathways involved remain poorly characterized. Here we show that
      <protein>integrin-linked kinase (ILK)</protein>, a <protein>59-kDa serine-threonine protein kinase</protein>
      that interacts principally with <protein>beta(1) integrins</protein>, is highly expressed in
      human mononuclear cells and is activated by exposure of leukocytes to the
      <protein>chemokine monocyte chemoattractant protein-1</protein>. Biochemical inhibitor
      studies show that <protein>chemokine</protein>-triggered activation of <protein>ILK</protein> is downstream of
      <protein>phosphoinositide 3-kinase</protein>. In functional assays under physiologically
      relevant flow conditions, overexpression of wild-type <protein>ILK</protein> in human
      monocytic cells diminishes <protein>beta(1) integrin</protein>/<protein>vascular cell adhesion
      molecule-1</protein>-dependent firm adhesion to human endothelial cells. These data
      implicate <protein>ILK</protein> in the dynamic signaling events involved in the regulation
      of <protein>leukocyte integrin</protein> avidity for endothelial substrates.
</DOC>
<DOC>
<DOC_ID>[38]</DOC_ID>
>38.NF00133088
PMID:11809755
TI  - <protein>Insulin-degrading enzyme</protein> rapidly removes the <protein>beta-amyloid precursor
      protein</protein> intracellular domain (AICD).
AB  - The <protein>intramembranous gamma-secretase</protein> cleavage of the <protein>beta-amyloid precursor
      protein (APP)</protein> is dependent on biologically active <protein>presenilins (PS)</protein>. <protein>Notch</protein>
      also undergoes a similar <protein>PS</protein>-dependent <protein>gamma-secretase</protein>-like cleavage,
      resulting in the liberation of the <protein>Notch</protein> intracellular domain (NICD),
      which is critically required for developmental signal transduction.
      <protein>gamma-Secretase</protein> processing of <protein>APP</protein> results in the production of a similar
      fragment called AICD (<protein>APP</protein> intracellular domain), which may function in
      nuclear signaling as well. AICD, like NICD, is rapidly removed. By using a
      battery of <protein>protease</protein> inhibitors we demonstrate that AICD, in contrast to
      NICD, is degraded by a <protein>cytoplasmic metalloprotease</protein>. In vitro degradation
      of AICD can be reconstituted with cytoplasmic fractions obtained from
      neuronal and non-neuronal cells. Taking into account the inhibition
      profile and the cytoplasmic localization, we identified three candidate
      enzymes (<protein>neurolysin</protein>, <protein>thimet oligopeptidase</protein>, and <protein>insulin-degrading enzyme
      (IDE)</protein>, also known as <protein>insulysin</protein>), which all are involved in the degradation
      of bioactive peptides in the brain. When <protein>insulin</protein>, a well characterized
      substrate of <protein>IDE</protein>, was added to the in vitro degradation assay, removal of
      AICD was efficiently blocked. Moreover, overexpression of <protein>IDE</protein> resulted in
      enhanced degradation of AICD, whereas overexpression of the inactive <protein>IDE</protein>
      E111Q mutant did not affect AICD degradation. Finally, immunodepletion of
      <protein>IDE</protein> significantly reduced the AICD degrading activity. Therefore our data
      demonstrate that <protein>IDE</protein>, which is one of the <protein>proteases</protein> implicated in the
      removal of extracellular Abeta, also removes the cytoplasmic product of
      <protein>gamma-secretase</protein> cleaved <protein>APP</protein>.
</DOC>
<DOC>
<DOC_ID>[39]</DOC_ID>
>39.NF00122477
PMID:12508640
TI  - [Mutation analysis of <protein>KLF6</protein> gene in human nasopharyngeal carcinomas]
AB  - BACKGROUND &amp; OBJECTIVE: Nasopharyngeal carcinoma (NPC) is one of the most
      common cancers in South China and Southeast Asia. The etiological factor
      is believed to be the interaction between genetic susceptibility, EBV
      infection and environmental factors, involved in the multi-step process of
      carcinogenesis and development of NPC. However, the molecular pathology of
      NPC is unclear yet. <protein>Kruppel-like factor 6(KLF6)</protein> is a ubiquitously
      expressed <protein>nuclear transcription factor</protein>, which is deleted and/or mutated
      with high frequency in a subset of prostate cancer. This study was
      designed to investigate <protein>KLF6</protein> mutation in NPC tumors and NPC cell lines.
      METHODS: Genomic DNAs from 19 NPC tumor biospies and 3 NPC cell lines were
      used in mutation detection of <protein>KLF6</protein> coding region and splice sites by
      PCR-sequencing. 100 chromosomes from 50 random healthy individuals were
      used as control. RESULTS: In 3 of 19 NPC tissues, 3 different mutations
      (Glu75Val, Ser136Arg, Arg243 Lys) in <protein>KLF6</protein> gene were found by
      PCR-sequencing. None of the 3 mutations were detected in the 50 random
      healthy individuals. CONCLUSION: <protein>KLF6</protein> gene may be involved in
      carcinogenesis of sporadic NPC.
</DOC>
<DOC>
<DOC_ID>[40]</DOC_ID>
>40.NF00085672
PMID:11700562
TI  - Identification of the <protein>cellular receptor</protein> for <long_form>anthrax <protein>toxin</protein></long_form>.
AB  - The <protein>tripartite toxin</protein> secreted by Bacillus anthracis, the causative agent
      of anthrax, helps the bacterium evade the immune system and can kill the
      host during a systemic infection. Two <protein>components of the toxin</protein>
      enzymatically modify substrates within the cytosol of mammalian cells:
      <protein>oedema factor (OF)</protein> is an <protein>adenylate cyclase</protein> that impairs host defences
      through a variety of mechanisms including inhibiting phagocytosis; <protein>lethal
      factor (LF)</protein> is a <protein>zinc-dependent protease</protein> that cleaves <protein>mitogen-activated
      protein kinase kinase</protein> and causes lysis of macrophages. <protein>Protective antigen
      (PA)</protein>, the third component, binds to a <protein>cellular receptor</protein> and mediates
      delivery of the enzymatic components to the cytosol. Here we describe the
      cloning of the <long_form>human <protein>PA receptor</protein></long_form> using a genetic complementation approach.
      The <protein>receptor</protein>, termed <protein>ATR (anthrax toxin receptor)</protein>, is a <protein>type I membrane
      protein</protein> with an extracellular von Willebrand factor A domain that binds
      directly to <protein>PA</protein>. In addition, a soluble version of this domain can protect
      cells from the action of the <protein>toxin</protein>.
</DOC>
<DOC>
<DOC_ID>[41]</DOC_ID>
>41.NF00098308
PMID:11470784
TI  - An isoform-specific inhibitory domain regulates the <protein>LHX3 LIM homeodomain
      factor holoprotein</protein> and the production of a functional alternate
      translation form.
AB  - The <protein>LHX3 LIM homeodomain transcription factor</protein> is required for pituitary
      development and motor neuron specification. The <protein>Lhx3</protein> gene encodes two
      isoforms, <protein>LHX3a</protein> and <protein>LHX3b</protein>, that differ in their amino-terminal sequences.
      Humans and mice with defective <protein>Lhx3</protein> genes are deficient in gonadotrope,
      lactotrope, somatotrope, and thyrotrope pituitary cells. We show that,
      whereas <protein>Lhx3b</protein> is highly expressed in these <protein>Lhx3</protein>-dependent cell types, high
      levels of <protein>Lhx3a</protein> expression are restricted to <protein>alpha glycoprotein
      subunit</protein>-expressing thyrotropes and gonadotropes. Cross-species comparison
      reveals the <protein>LHX3b</protein>-specific domain is more conserved than the
      <protein>LHX3a</protein>-specific domain. We demonstrate that the <protein>LHX3b</protein>-specific domain is a
      transferable inhibitor that reduces gene activation and DNA binding by
      <protein>homeodomain proteins</protein>. In addition, we identify a novel <protein>LHX3 protein</protein>
      (<protein>M2-LHX3</protein>) and determine that this molecule is generated by an internal
      translation initiation codon. The <protein>LHX3a</protein>- and <protein>LHX3b</protein>-specific coding
      sequences regulate differential usage of this internal start codon.
      Further, we identify the major activation domain of <protein>LHX3</protein> in the carboxyl
      terminus of the molecule. <protein>M2-LHX3</protein> is active because it retains this domain
      and binds DNA better than <protein>LHX3a</protein> or <protein>LHX3b</protein>. Other <protein>LIM homeodomain</protein> genes,
      including <protein>Lhx4</protein>, generate similar truncated proteins. These studies
      describe how transcriptional regulatory genes can generate multiple
      functional proteins.
</DOC>
<DOC>
<DOC_ID>[42]</DOC_ID>
>42.NF00094668
PMID:11701952
TI  - Comparative FISH mapping of <protein>Gab1</protein> and <protein>Gab2</protein> genes in human, mouse and rat.
AB  - <protein>Gab1</protein> and <protein>Gab2</protein> are members of the <protein>Gab</protein> family which act as adapters for
      transmitting various signals in response to stimuli through <protein>cytokine</protein> and
      <protein>growth factor receptors</protein>, and <long_form>T- and <protein>B-cell antigen receptors</protein></long_form>. We
      determined chromosome locations of the two genes in human, mouse and rat
      by fluorescence in situ hybridization. The <protein>Gab1</protein> gene was localized to
      chromosome 4q31.1 in human, 8C3 in mouse and 19q11.1--&gt; q11.2 in rat, and
      the <protein>Gab2</protein> gene was located on chromosome 11q13.4--&gt;q13.5 in human, 7E2 in
      mouse and 1q33.2--&gt;q33.3 in rat. All human, mouse and <long_form>rat <protein>Gab1</protein></long_form> and <protein>Gab2</protein>
      genes were localized to chromosome regions where conserved homology has
      been identified among the three species.
</DOC>
<DOC>
<DOC_ID>[43]</DOC_ID>
>43.NF00926992
PMID:11799131
TI  - Molecular mechanics of <protein>cardiac titin</protein>'s PEVK and N2B spring elements.
AB  - <protein>Titin</protein> is a giant <protein>elastic protein</protein> that is responsible for the majority of
      passive force generated by the myocardium. <protein>Titin</protein>'s force is derived from
      its extensible I-band region, which, in the cardiac isoform, comprises
      three main extensible elements: tandem Ig segments, the PEVK domain, and
      the N2B unique sequence (N2B-Us). Using atomic force microscopy, we
      characterized the single molecule force-extension curves of the PEVK and
      N2B-Us spring elements, which together are responsible for physiological
      levels of passive force in moderately to highly stretched myocardium.
      Stretch-release force-extension curves of both the PEVK domain and N2B-Us
      displayed little hysteresis: the stretch and release data nearly
      overlapped. The force-extension curves closely followed worm-like chain
      behavior. Histograms of persistence length (measure of chain bending
      rigidity) indicated that the single molecule persistence lengths are
      approximately 1.4 and approximately 0.65 nm for the PEVK domain and
      N2B-Us, respectively. Using these mechanical characteristics and those
      determined earlier for the tandem Ig segment (assuming folded Ig domains),
      we modeled the <protein>cardiac titin</protein> extensible region in the sarcomere and
      calculated the extension of the various spring elements and the forces
      generated by <protein>titin</protein>, both as a function of sarcomere length. In the
      physiological sarcomere length range, predicted values and those obtained
      experimentally were indistinguishable.
</DOC>
<DOC>
<DOC_ID>[44]</DOC_ID>
>44.NF00866488
PMID:12359327
TI  - Characterisation and expression analysis of the <protein>WDR9</protein> gene, located in the
      Down critical region-2 of the human chromosome 21.
AB  - We report the isolation and characterisation of the gene <protein>WDR9 (WD Repeat
      9)</protein>, located in the Down Syndrome critical region-2 (DCR-2) from the human
      chromosome 21. This gene spans 125 kb of genomic sequence and is organised
      in 41 exons and 40 introns. The <protein>WDR9</protein> cDNA has a size of 13 kb and encodes
      for a putative protein of 2269 amino acids with a potential location in
      the nucleus. Expression analysis in different human adult tissues and in
      cultured cell lines indicates that the gene has several tissue-specific
      transcripts. The more significant protein signatures in the <protein>WDR9 protein</protein>
      sequence are for WD repeats, bromodomain, <protein>beta-ketoacyl synthases</protein>, and
      <protein>ribonucleoprotein (RNP)</protein>. The <protein>WDR9 protein</protein> has a high similarity with the
      Mus musculus <protein>neuronal differentiation protein (NDRP)</protein> and a region of
      similarity with the region of the <protein>Yotiao protein</protein> that has been proposed to
      bind the <protein>NR1 subunit of the NMDA receptor</protein>. The presence of protein-protein
      interaction domains as such the WD repeats, and the similarity of the <protein>WDR9
      protein</protein> to <protein>regulatory proteins</protein> suggest a potential involvement in some of
      the clinical features associated to the DCR-2.
</DOC>
<DOC>
<DOC_ID>[45]</DOC_ID>
>45.NF00103850
PMID:12029094
TI  - <protein>Metallochaperone Atox1</protein> transfers copper to the NH2-terminal domain of the
      <protein>Wilson's disease protein</protein> and regulates its catalytic activity.
AB  - Copper is essential for the growth and development of mammalian cells. The
      key role in the intracellular distribution of copper belongs to the
      recently discovered family of <protein>metallochaperones</protein> and to <protein>copper-transporting
      P-type ATPases</protein>. The mutations in the <protein>ATPase ATP7B</protein>, the <protein>Wilson's disease
      protein (WNDP)</protein>, lead to intracellular accumulation of copper and severe
      hepatic and neurological abnormalities. Several of these mutations were
      shown to disrupt the protein-protein interactions between <protein>WNDP</protein> and the
      <protein>metallochaperone Atox1</protein>, suggesting that these interactions are important
      for normal copper homeostasis. To understand the functional consequences
      of the <protein>Atox1</protein>-<protein>WNDP</protein> interaction at the molecular level, we produced
      recombinant <protein>Atox1</protein> and characterized its effects on <protein>WNDP</protein>. We demonstrate
      that <protein>Atox1</protein> transfers copper to the purified amino-terminal domain of <protein>WNDP</protein>
      (N-<protein>WNDP</protein>) in a dose-dependent and saturable manner. A maximum of six copper
      atoms can be transferred to N-<protein>WNDP</protein> by the <protein>chaperone</protein>. Furthermore, the
      incubation of copper <protein>Atox1</protein> with the full-length <protein>WNDP</protein> leads to the
      stimulation of the <protein>WNDP</protein> catalytic activity, providing strong evidence for
      the direct effect of <protein>Atox1</protein> on the function of this <protein>transporter</protein>. Our data
      also suggest that <protein>Atox1</protein> can regulate the copper occupancy of <protein>WNDP</protein>. The
      incubation with apo-<protein>Atox1</protein> results in the removal of copper from the
      metalated N-<protein>WNDP</protein> and apparent down-regulation of <protein>WNDP</protein> activity.
      Interestingly, at least one copper atom remains tightly bound to N-<protein>WNDP</protein>
      even in the presence of excess apo-<protein>Atox1</protein>. We suggest that this incomplete
      reversibility reflects the functional non-equivalency of the metal-binding
      sites in <protein>WNDP</protein> and speculate about the intracellular consequences of the
      reversible <protein>Atox1</protein>-mediated copper transfer.
</DOC>
<DOC>
<DOC_ID>[46]</DOC_ID>
>46.NF00116407
PMID:11816009
TI  - Development of a rapid and sensitive high-performance liquid
      chromatographic method to determine <protein>CYP2D6</protein> phenotype in human liver
      microsomes.
AB  - Dextromethorphan is a probe substrate to determine <protein>CYP2D6</protein> phenotype. The
      conversion of dextromethorphan to dextrorphan by <protein>CYP2D6</protein> accounts for
      approximately 60% of total metabolism. Most analytical methods utilize
      complicated labor- and time-intensive sample processing methods with
      several liquid-liquid extraction (LLE) steps. Our goal was to develop a
      non-LLE based rapid and sensitive HPLC method, to measure dextromethorphan
      metabolism in human liver microsomes. A solid-phase filtration based
      reverse-phase HPLC method with fluorescence detection was developed and
      validated. Human liver (n = 6) microsomal incubations were carried out
      with dextromethorphan, under optimum conditions. The analytes were
      separated by one-step centrifugal filtration with Nanosep separation
      units. The filtrate was injected ( 50 microL) into a Waters Alliance 2690
      HPLC system. Metabolic incubations were also conducted to determine levels
      using LLE for comparisons. The Nanosep separation step reduced the
      extraction time from 3h to 40 min. The limit of quantitation was 23.8 nM
      (9.7 ng/mL), recovery was approximately 98%, the mean precision values
      were &lt;10% RSD for the controls (80, 320 and 640 nM) and mean percentage
      error was &lt;5%. Michaelis-Menten parameters were determined to distinguish
      <protein>CYP2D6</protein> phenotypes. A rapid and sensitive HPLC method is reported, which
      may be suitable for automation and allows phenotyping of human liver
      microsomes.
</DOC>
<DOC>
<DOC_ID>[47]</DOC_ID>
>47.NF00125317
PMID:12359228
TI  - Identification of a novel <long_form>human <protein>nicotinamide mononucleotide
      adenylyltransferase</protein></long_form>.
AB  - The enzyme <protein>nicotinamide mononucleotide adenylyltransferase</protein> is an
      ubiquitous enzyme catalyzing an essential step in NAD (NADP) biosynthetic
      pathway. In human cells, the <protein>nuclear enzyme</protein>, which we will now call
      <protein>NMNAT-1</protein>, has been the only known enzyme of this type for over 10 years.
      Here we describe the cloning and expression of a human cDNA encoding a
      novel <protein>34.4kDa protein</protein>, that shares significant homology with the <protein>31.9kDa
      NMNAT-1</protein>. We propose to call this enzyme <protein>NMNAT-2</protein>. Purified recombinant
      <protein>NMNAT-2</protein> is endowed with <protein>NMN and nicotinic acid mononucleotide
      adenylyltransferase</protein> activities, but differs from <protein>NMNAT-1</protein> with regard to
      chromosomal and cellular localization, tissue-specificity of expression,
      and molecular properties, supporting the idea that the two enzymes might
      play distinct physiological roles in NAD homeostasis.
</DOC>
<DOC>
<DOC_ID>[48]</DOC_ID>
>48.NF00131475
PMID:12584323
TI  - <protein>Furin</protein> processing and proteolytic activation of Semliki Forest virus.
AB  - The alphavirus Semliki Forest virus (SFV) infects cells via a
      low-pH-dependent membrane fusion reaction mediated by the <protein>E1 envelope
      protein</protein>. Fusion is regulated by the interaction of E1 with the
      <protein>receptor-binding protein E2</protein>. E2 is synthesized as a precursor termed
      &quot;<protein>p62</protein>,&quot; which forms a stable heterodimer with E1 and is processed late in
      the secretory pathway by a <protein>cellular furin-like protease</protein>. Once processing
      to E2 occurs, the E1/E2 heterodimer is destabilized so that it is more
      readily dissociated by exposure to low pH, allowing fusion and infection.
      We have used FD11 cells, a <protein>furin</protein>-deficient CHO cell line, to characterize
      the processing of <protein>p62</protein> and its role in the control of virus fusion and
      infection. <protein>p62</protein> was not cleaved in FD11 cells and cleavage was restored in
      FD11 cell transfectants expressing <long_form>human <protein>furin</protein></long_form>. Studies of unprocessed
      virus produced in FD11 cells (wt/<protein>p62</protein>) demonstrated that the <protein>p62 protein</protein>
      was efficiently cleaved by purified <protein>furin</protein> in vitro, without requiring
      prior exposure to low pH. wt/<protein>p62</protein> virus particles were also processed
      during their endocytic uptake in <protein>furin</protein>-containing cells, resulting in more
      efficient virus infection. wt/<protein>p62</protein> virus was compared with mutant L, in
      which <protein>p62</protein> cleavage was blocked by mutation of the <protein>furin</protein>-recognition motif.
      wt/<protein>p62</protein> and mutant L had similar fusion properties, requiring a much lower
      pH than control virus to trigger fusion and fusogenic E1 conformational
      changes. However, the in vivo infectivity of mutant L was more strongly
      inhibited than that of wt/<protein>p62</protein>, due to additional effects of the mutation
      on virus-cell binding.
</DOC>
<DOC>
<DOC_ID>[49]</DOC_ID>
>49.NF00105475
PMID:12359356
TI  - <protein>Microsomal epoxide hydrolase</protein> and <protein>glutathione S-transferase</protein> polymorphisms
      in relation to laryngeal carcinoma risk.
AB  - Two polymorphic sites of the <protein>microsomal epoxide hydrolase</protein> gene (<protein>EPHX1</protein>,
      113Tyr--&gt;113His, 139His--&gt;139Arg) and four <protein>glutathione S-transferase</protein> genes
      (<protein>GSTM1</protein>, <protein>GSTM3</protein>, <protein>GSTP1</protein>, <protein>GSTT1</protein>) were genotyped in a group of patients with
      larynx cancer (N=204) and in a group of healthy controls (N=203), all
      Spanish caucasians. After adjusting for gender, age, and tobacco smoking,
      none of the polymorphisms alone were found to be associated with larynx
      cancer risk. The analysis of <protein>EPHX1</protein>/<protein>GST</protein> combinations, however, showed a
      significant over-representation of patients with a combination of
      113Tyr/113Tyr <protein>EPHX1</protein> and 105Ile/105Ile <protein>GSTP1</protein> (adjusted odds ratio (OR):
      1.95; 95% confidence interval (CI): 1.02-3.78). The calculation of the
      predicted <protein>epoxide hydrolase (EH)</protein> activity also showed an increased risk
      for the individuals with both predicted high activity <protein>EH</protein> and 105Ile/105Ile
      <protein>GSTP1</protein> (OR: 2.90; 95% CI: 1.10-7.67). These results on larynx cancer tend
      to confirm a former study on lung cancer (Cancer Lett. 173 (2001) 155)
      suggesting the existence of an interaction between variants of <protein>EH</protein> and
      <protein>GSTpi</protein>, both enzymes being involved in the metabolism of aromatic
      hydrocarbons, that may increase susceptibility to tobacco-related cancers.
</DOC>
<DOC>
<DOC_ID>[50]</DOC_ID>
>50.NF00106528
PMID:11778160
TI  - A 117-kb microdeletion removing <long_form><protein>HOXD9</protein>-<protein>HOXD13</protein></long_form> and <protein>EVX2</protein> causes
      synpolydactyly.
AB  - Studies in mouse and chick have shown that the 5' <protein>HoxD</protein> genes play major
      roles in the development of the limbs and genitalia. In humans, mutations
      in <protein>HOXD13</protein> cause the dominantly inherited limb malformation synpolydactyly
      (SPD). Haploinsufficiency for the 5' <protein>HOXD</protein> genes has recently been proposed
      to underlie the monodactyly and penoscrotal hypoplasia in two children
      with chromosomal deletions encompassing the entire <protein>HOXD</protein> cluster. Similar
      deletions, however, have previously been associated with split-hand/foot
      malformation (SHFM), including monodactyly. Here we report a father and
      daughter with SPD who carry a 117-kb microdeletion at the 5' end of the
      <protein>HOXD</protein> cluster. By sequencing directly across the deletion breakpoint, we
      show that this microdeletion removes only <long_form><protein>HOXD9</protein>-<protein>HOXD13</protein></long_form> and <protein>EVX2</protein>. We also
      report a girl with bilateral split foot and a chromosomal deletion that
      includes the entire <protein>HOXD</protein> cluster and extends approximately 5 Mb
      centromeric to it. Our findings indicate that haploinsufficiency for the
      5' <protein>HOXD</protein> genes causes not SHFM but SPD and point to the presence of a novel
      locus for SHFM in the interval between <protein>EVX2</protein> and <protein>D2S294</protein>. They also suggest
      that there is a regulatory region, upstream of the <protein>HOXD</protein> cluster, that is
      responsible for activating the cluster as a whole.
</DOC>
<DOC>
<DOC_ID>[51]</DOC_ID>
>51.NF00131477
PMID:12050117
TI  - <protein>Mastermind</protein> mediates chromatin-specific transcription and turnover of the
      <protein>Notch enhancer complex</protein>.
AB  - Signaling through the <protein>Notch</protein> pathway activates the proteolytic release of
      the <protein>Notch</protein> intracellular domain (ICD), a dedicated <protein>transcriptional
      coactivator of CSL enhancer-binding proteins</protein>. Here we show that
      chromatin-dependent transactivation by the recombinant <long_form><protein>Notch</protein> ICD-<protein>CBF1
      enhancer complex</protein></long_form> in vitro requires an additional coactivator, <protein>Mastermind
      (MAM)</protein>. <protein>MAM</protein> provides two activation domains necessary for <protein>Notch</protein> signaling
      in mammalian cells and in Xenopus embryos. We show that the central <protein>MAM</protein>
      activation domain (TAD1) recruits <protein>CBP</protein>/<protein>p300</protein> to promote nucleosome
      acetylation at <protein>Notch enhancers</protein> and activate transcription in vitro. We
      also find that <protein>MAM</protein> expression induces phosphorylation and relocalization
      of endogenous <protein>CBP</protein>/<protein>p300 proteins</protein> to nuclear foci in vivo. Moreover, we show
      that coexpression with <protein>MAM</protein> and <protein>CBF1</protein> strongly enhances phosphorylation and
      proteolytic turnover of the <protein>Notch</protein> ICD in vivo. Enhanced phosphorylation of
      the ICD and <protein>p300</protein> requires a glutamine-rich region of <protein>MAM</protein> (TAD2) that is
      essential for <protein>Notch</protein> transcription in vivo. Thus <protein>MAM</protein> may function as a
      timer to couple transcription activation with disassembly of the <protein>Notch
      enhancer complex</protein> on chromatin.
</DOC>
<DOC>
<DOC_ID>[52]</DOC_ID>
>52.NF00111959
PMID:12209014
TI  - Dual localization of <long_form>human <protein>DNA topoisomerase IIIalpha</protein></long_form> to mitochondria and
      nucleus.
AB  - The <long_form>human <protein>TOP3alpha</protein></long_form> gene encoding <protein>DNA topoisomerase IIIalpha (hTop3alpha)</protein>
      has two potential start codons for the synthesis of proteins 1,001 and 976
      aa residues in length. The sequence of the N-terminal region of the
      1,001-residue form resembles signal peptide sequences for mitochondrial
      import, and fluorescence microscopy shows that the addition of as few as
      the first 34 aa of the <protein>1,001-residue form of hTop3alpha</protein> to a green
      fluorescent protein can direct the chimeric protein to mitochondria.
      Biochemical analyses of subcellular fractions of HeLa cells further
      demonstrate that a distinctive fraction of <protein>hTop3alpha</protein> is present inside
      mitochondria, as evidenced by its resistance to <protein>proteinase K</protein>. This
      fraction constitutes several percent of the enzyme in the nuclear
      fraction, suggesting that the distribution of the <long_form>mitochondrial and
      <protein>nuclear forms of hTop3alpha</protein></long_form> is roughly in proportion to the DNA contents
      of these cellular compartments. The presence of a <protein>type IA DNA
      topoisomerase</protein> in the mitochondria of other eukaryotes is supported by an
      examination of the amino acid sequences of mouse and <long_form>Drosophila <protein>DNA
      topoisomerase IIIalpha</protein></long_form> and <long_form>Schizosaccharomyces pombe <protein>DNA topoisomerase</protein>
      <protein>III</protein></long_form>. Given the presence of at least one <protein>type IA DNA topoisomerase</protein> in all
      forms of life examined to date, the finding of a type IA enzyme in
      mitochondria further supports the notion of a key role of such enzymes in
      DNA transactions.
</DOC>
<DOC>
<DOC_ID>[53]</DOC_ID>
>53.NF00095807
PMID:12140183
TI  - <protein>Spectrin</protein>-like repeats from <protein>dystrophin</protein> and <protein>alpha-actinin-2</protein> are not
      functionally interchangeable.
AB  - Mutations in the <protein>dystrophin</protein> gene result in Duchenne muscular dystrophy
      (DMD). <protein>Dystrophin</protein> is a multidomain protein that functions to stabilize the
      sarcolemmal membrane during muscle contraction. The central rod domain has
      been proposed to act as a shock absorber, as a force transducer or as a
      spacer separating important N- and C-terminal domains that interact with
      <protein>actin</protein> and the <long_form><protein>dystrophin</protein>-<protein>glycoprotein</protein> complex (DGC)</long_form>. Structure/function
      studies demonstrated that deletion of large portions of the rod domain can
      result in the production of smaller, yet highly functional, <protein>dystrophin</protein>
      <protein>proteins</protein>. In a dramatic example, a 'micro-<protein>dystrophin</protein>' transgene containing
      only four <protein>dystrophin</protein> <protein>spectrin</protein>-like repeats resulted in complete correction
      of most of the symptoms associated with dystrophy in the mdx mouse model
      for DMD. <protein>Dystrophin</protein> shares considerable homology with the multidomain,
      <protein>actin-crosslinking protein alpha-actinin</protein>. To explore the hypothesis that
      the <protein>dystrophin</protein> rod domain acts as a spacer region, a chimeric
      micro-<protein>dystrophin</protein> transgene containing the four-repeat rod domain of
      <protein>alpha-actinin-2</protein> was expressed in mdx mice. This chimeric transgene was
      incapable of correcting the morphological pathology of the mdx mouse, but
      still functioned to assemble the <protein>DGC</protein> at the membrane and provided some
      protection from contraction-induced injury. These data demonstrated that
      different <protein>spectrin</protein>-like repeats are not equivalent, and reinforced the
      suggestion that the <protein>dystrophin</protein> rod domain is not merely a spacer but
      likely contributes an important mechanical role to overall <protein>dystrophin</protein>
      function.
</DOC>
<DOC>
<DOC_ID>[54]</DOC_ID>
>54.NF00087464
PMID:12062429
TI  - The <protein>dystrophin</protein> gene is alternatively spliced throughout its coding
      sequence.
AB  - We have analysed splicing patterns in the <long_form>human <protein>dystrophin</protein></long_form> gene region
      encoding the rod and cysteine-rich domains in normal skeletal muscle,
      brain and heart tissues. Sixteen novel alternative transcripts were
      identified, the majority of them being present in all three tissues.
      Tissue-specific variants were also identified, suggesting a functional
      role of transcriptional diversity. Transcript analysis in
      dystrophinopathic autoptic and bioptic specimens revealed that pre-mRNAs
      secondary structure formation and relative strength of exon/exon
      association play little or no role in directing alternative splicing
      events. This analysis also showed that independent deletion events leading
      to the loss of the same exons may be associated with transcriptional
      variability.
</DOC>
<DOC>
<DOC_ID>[55]</DOC_ID>
>55.NF00095564
PMID:12065429
TI  - <protein>Drf1</protein>, a novel <protein>regulatory subunit for human Cdc7 kinase</protein>.
AB  - Studies in model organisms have contributed to elucidate multiple levels
      at which regulation of eukaryotic DNA replication occurs. <protein>Cdc7</protein>, an
      evolutionarily conserved <protein>serine-threonine kinase</protein>, plays a pivotal role in
      linking cell cycle regulation to genome duplication, being essential for
      the firing of DNA replication origins. Binding of the <protein>cell cycle-regulated
      subunit Dbf4</protein> to <protein>Cdc7</protein> is necessary for in vitro <protein>kinase</protein> activity. This
      binding is also thought to be the key regulatory event that controls <protein>Cdc7</protein>
      activity in cells. Here, we describe a novel human protein, <protein>Drf1</protein>, related
      to both human and <long_form>yeast <protein>Dbf4</protein></long_form>. <protein>Drf1</protein> is a <protein>nuclear cell cycle-regulated
      protein</protein>, it binds to <protein>Cdc7</protein> and activates the <protein>kinase</protein>. Therefore, <long_form>human <protein>Cdc7</protein></long_form>,
      like <protein>cyclin-dependent kinases</protein>, can be activated by alternative <protein>regulatory
      subunits</protein>. Since the <protein>Drf1</protein> gene is either absent or not yet identified in
      the genome of model organisms such as yeast and Drosophila, these findings
      introduce a new level of complexity in the regulation of DNA replication
      of the human genome.
</DOC>
<DOC>
<DOC_ID>[56]</DOC_ID>
>56.NF01154885
PMID:12075506
TI  - Mandibuloacral dysplasia is caused by a mutation in <protein>LMNA</protein>-encoding <protein>lamin
      A/C</protein>.
AB  - Mandibuloacral dysplasia (MAD) is a rare autosomal recessive disorder,
      characterized by postnatal growth retardation, craniofacial anomalies,
      skeletal malformations, and mottled cutaneous pigmentation. The <protein>LMNA</protein> gene
      encoding two <protein>nuclear envelope proteins</protein> (<protein>lamins A and C [lamin A/C]</protein>) maps
      to chromosome 1q21 and has been associated with five distinct pathologies,
      including Dunnigan-type familial partial lipodystrophy, a condition that
      is characterized by subcutaneous fat loss and is invariably associated
      with <protein>insulin</protein> resistance and diabetes. Since patients with MAD frequently
      have partial lipodystrophy and <protein>insulin</protein> resistance, we hypothesized that
      the disease may be caused by mutations in the <protein>LMNA</protein> gene. We analyzed five
      consanguineous Italian families and demonstrated linkage of MAD to
      chromosome 1q21, by use of homozygosity mapping. We then sequenced the
      <protein>LMNA</protein> gene and identified a homozygous missense mutation (R527H) that was
      shared by all affected patients. Patient skin fibroblasts showed nuclei
      that presented abnormal <protein>lamin A/C</protein> distribution and a dysmorphic envelope,
      thus demonstrating the pathogenic effect of the R527H <protein>LMNA</protein> mutation.
</DOC>
<DOC>
<DOC_ID>[57]</DOC_ID>
>57.NF00866570
PMID:11938494
TI  - The <protein>TRIM37</protein> gene encodes a <protein>peroxisomal RING-B-box-coiled-coil protein</protein>:
      classification of mulibrey nanism as a new peroxisomal disorder.
AB  - Mulibrey nanism is a rare growth disorder of prenatal onset caused by
      mutations in the <protein>TRIM37</protein> gene, which encodes a <protein>RING-B-box-coiled-coil
      protein</protein>. The pathogenetic mechanisms of mulibrey nanism are unknown. We
      have used transiently transfected cells and antibodies raised against the
      predicted <protein>TRIM37 protein</protein> to characterize the <protein>TRIM37</protein> gene product and to
      determine its intracellular localization. We show that the <long_form>human <protein>TRIM37</protein></long_form>
      cDNA encodes a <protein>peroxisomal protein</protein> with an apparent molecular weight of
      130 kD. Peroxisomal localization is compromised in mutant protein
      representing the major Finnish <protein>TRIM37</protein> mutation but is retained in the
      protein representing the minor Finnish mutation. Colocalization of
      endogenous <protein>TRIM37</protein> with peroxisomal markers was observed by double
      immunofluorescence staining in HepG2 and human intestinal smooth muscle
      cell lines. In human tissue sections, <protein>TRIM37</protein> shows a granular cytoplasmic
      pattern. Endogenous <protein>TRIM37</protein> is not imported into peroxisomes in <protein>peroxin 1</protein>
      (<protein>PEX1</protein>(-/-)) and <protein>peroxin 5</protein> (<protein>PEX5</protein>(-/-)) mutant fibroblasts but is imported
      normally in <protein>peroxin 7</protein> (<protein>PEX7</protein>(-/-)) deficient fibroblasts, giving further
      evidence for a peroxisomal localization of <protein>TRIM37</protein>. Fibroblasts derived
      from patients with mulibrey nanism lack C-terminal <protein>TRIM37</protein> immunoreactivity
      but stain normally for both peroxisomal matrix and membrane markers,
      suggesting apparently normal peroxisome biogenesis in patient fibroblasts.
      Taken together, this molecular evidence unequivocally indicates that
      <protein>TRIM37</protein> is located in the peroxisomes, and Mulibrey nanism thus can be
      classified as a new peroxisomal disorder.
</DOC>
<DOC>
<DOC_ID>[58]</DOC_ID>
>58.NF01119975
PMID:12210501
TI  - Blocking the <protein>translation elongation factor-1 delta</protein> with its antisense mRNA
      results in a significant reversal of its oncogenic potential.
AB  - In spite of the strong evidence for the carcinogenic activity of cadmium
      and its related compounds, the underlying molecular mechanisms that lead
      to malignant transformation in cells exposed to cadmium remain unknown.
      Recently, Joseph et al. [J. Biol. Chem. 227:6131-6136, 2002] have
      identified, cloned, and characterized the <long_form>mouse <protein>Translation Elongation
      Factor-1 delta sub-unit</protein></long_form> (<protein>TEF-1 delta</protein>, GenBank Accession Number AF304351)
      as a novel cadmium-responsive proto-oncogene. Presently, additional
      studies regarding the oncogenic potential of <protein>TEF-1 delta</protein> have been carried
      out. Transfection of NIH3T3 cells with the pcDNA3.1 expression vector
      containing the <protein>TEF-1 delta</protein> cDNA in the sense (5'--&gt;3') orientation
      resulted in overexpression of the encoded 31 kDa protein.
      Transfection-mediated overexpression of <protein>TEF-1 delta protein</protein> resulted in
      transformation of the cells as evidenced from the appearance of
      transformed foci. Cotransfection of the cells with a mixture of plasmid
      DNA consisting of <protein>TEF-1 delta</protein> cDNA in the sense (5'--&gt;3') and in the
      antisense (3'--&gt;5') orientation resulted in significant inhibition of
      translation of the <protein>TEF-1 delta protein</protein>. Antisense <protein>TEF-1 delta</protein>
      mRNA-mediated inhibition of translation of <protein>TEF-1 delta protein</protein>,
      furthermore, resulted in inhibition of <protein>TEF-1 delta</protein>-mediated transformation
      of NIH3T3 cells as evidenced from the decrease in the number of
      transformed foci. These results further confirm that overexpression of
      <protein>TEF-1 delta</protein> is oncogenic and the antisense <protein>TEF-1 delta</protein> mRNA expression
      reverses its oncogenic potential.
</DOC>
<DOC>
<DOC_ID>[59]</DOC_ID>
>59.NF01235968
PMID:11894099
TI  - An <protein>amino-acid taste receptor</protein>.
AB  - The sense of taste provides animals with valuable information about the
      nature and quality of food. Mammals can recognize and respond to a diverse
      repertoire of chemical entities, including sugars, salts, acids and a wide
      range of toxic substances. Several amino acids taste sweet or delicious
      (umami) to humans, and are attractive to rodents and other animals. This
      is noteworthy because L-amino acids function as the building blocks of
      proteins, as biosynthetic precursors of many biologically relevant small
      molecules, and as metabolic fuel. Thus, having a taste pathway dedicated
      to their detection probably had significant evolutionary implications.
      Here we identify and characterize a <long_form>mammalian <protein>amino-acid taste receptor</protein></long_form>.
      This <protein>receptor</protein>, <protein>T1R1+3</protein>, is a <long_form>heteromer of the taste-specific <protein>T1R1</protein> and <protein>T1R3
      G-protein-coupled receptors</protein></long_form>. We demonstrate that <protein>T1R1</protein> and <protein>T1R3</protein> combine to
      function as a broadly tuned <protein>L-amino-acid sensor</protein> responding to most of the
      20 standard amino acids, but not to their D-enantiomers or other
      compounds. We also show that sequence differences in <protein>T1R receptors</protein> within
      and between species (human and mouse) can significantly influence the
      selectivity and specificity of taste responses.
</DOC>
<DOC>
<DOC_ID>[60]</DOC_ID>
>60.NF00866578
PMID:12081504
TI  - Activation mechanism of <protein>CDK2</protein>: role of <protein>cyclin</protein> binding versus
      phosphorylation.
AB  - Activation of the <protein>cyclin-dependent kinases</protein> is a two-step process involving
      <protein>cyclin</protein> binding followed by phosphorylation at a conserved threonine
      residue within the <protein>kinase</protein> activation loop. In this study, we describe the
      separate roles of <protein>cyclin A</protein> binding versus phosphorylation in the overall
      activation mechanism of <protein>CDK2</protein>. Interaction of <protein>CDK2</protein> with <protein>cyclin A</protein> results in
      a partially active complex that is moderately defective in the binding of
      the protein substrate, but not ATP, and severely defective in both
      phosphoryl group transfer and turnover. Alternatively, phosphorylation of
      the <protein>CDK2 monomer</protein> also results in a partially activated species, but one
      that is severely (&gt; or = 480-fold) defective in substrate binding
      exclusively. Catalytic turnover in the phosphorylated <protein>CDK2 monomer</protein> is
      largely unimpaired (approximately 8-fold lower). Our data support a model
      for the activation of <protein>CDK2</protein> in vivo, in which interaction of
      unphosphorylated <protein>CDK2</protein> with <protein>cyclin A</protein> serves to configure the active site
      for ground-state binding of both ATP and the protein substrate, and
      further aligns ATP in the transition state for phosphoryl transfer.
      Optimizing the alignment of protein substrates in the phosphoryl transfer
      reaction is the principal role of phosphorylation at Thr(160).
</DOC>
<DOC>
<DOC_ID>[61]</DOC_ID>
>61.NF00131800
PMID:11840488
TI  - Association analysis of polymorphisms at the <protein>interleukin-1</protein> locus in
      essential hypertension.
AB  - Infection with microorganisms such as Helicobacter pylori and Chlamydia
      pneumoniae has been associated with coronary heart disease (CAD) and
      hypertension (HT). Infection increases the release of <protein>pro-inflammatory
      cytokines</protein>, thus facilitating interactions that lead to vascular damage and
      other effects. We hypothesized that genetically determined differences in
      activity or responsiveness of <protein>cytokine</protein>(s) might contribute to HT. The
      <protein>interleukin-1</protein> gene (<protein>IL1</protein>) cluster on chromosome 2q14 contains three related
      genes (<protein>IL1A</protein>, <protein>IL1B</protein>, and <protein>IL1RN</protein>) located within a 430-kb region. These encode
      <protein>IL-1alpha</protein> and <protein>IL-1beta</protein>, as well as their endogenous <protein>receptor</protein> antagonist,
      <protein>IL-1ra</protein>. The <protein>IL1RN</protein> gene has a penta-allelic 86-bp tandem repeat in intron
      2. Allele <protein>IL1RN</protein>* 2 is associated with a wide range of chronic inflammatory
      and autoimmune conditions, and its combination with the -31T variant of an
      <protein>IL1B</protein> C(-31)T polymorphism constitutes a pro-inflammatory haplotype that
      leads to vigorous <protein>IL-1beta</protein> production. We therefore tested each of these
      polymorphisms for association with HT. Subjects were white Anglo-Celtic
      residents of Sydney, Australia. Frequencies of <protein>IL1B</protein> C(-31)T genotypes CC,
      CT, and TT were 0.50, 0.40, and 0.10 in normotensive (NT) and 0.46, 0.46,
      and 0.08 in HT, respectively (chi(2) = 1.2, P = 0.55). T allele frequency
      in NT (0.30) was similar to that in HT (0.31). For the <protein>IL1RN</protein> variant,
      frequencies of alleles <protein>IL1RN</protein>* 1 and * 2 and combined minor alleles * 3, *
      4, and * 5 were 0.61, 0.36, and 0.03 in NT and 0.54, 0.36, and 0.10 in HT,
      respectively (chi(2) = 11, P = 0.004). In conclusion, no association of
      the <protein>IL1B</protein> C(- 31)T with HT was found, whereas combined frequency of the
      minor alleles of the <protein>IL1RN</protein> polymorphism was increased in the HT cohort
      studied.
</DOC>
<DOC>
<DOC_ID>[62]</DOC_ID>
>62.NF00989995
PMID:12084581
TI  - Cloning and identification of a new member of <protein>water channel</protein> (<protein>AQP10</protein>) as an
      <protein>aquaglyceroporin</protein>.
AB  - Recently, a new member of <protein>aquaporins</protein> was reported as <protein>AQP10</protein> [Biochem.
      Biophys. Res. Commun. 287 (2001) 814], which is incompletely spliced to
      lose the sixth transmembrane domain and has poor water and no
      glycerol/urea permeabilities. Independently, we identified a similar clone
      in human. Our <protein>AQP10</protein> consists of 301 amino acids with a highly conserved
      sixth transmembrane domain. <protein>AQP10</protein> has higher identity with
      <protein>aquaglyceroporins</protein> (50% with <protein>AQP9</protein>, 48% with <protein>AQP3</protein>, 42% with <protein>AQP7</protein>) and lower
      identity with other <protein>aquaporins</protein> (32% with <protein>AQP1</protein> and <protein>AQP8</protein>). <protein>AQP10</protein> is
      expressed only in the small intestine with (approximately 2 kb). RNase
      protection assay revealed the absence of the unspliced form, supporting
      the authenticity of our clone. When expressed in Xenopus oocytes, <protein>AQP10</protein>
      stimulated osmotic water permeability sixfold in a mercury-sensitive
      manner. Glycerol and urea uptakes were also stimulated, while adenine
      uptake was not. The genome structure of <protein>AQP10</protein> is similar to those of other
      <protein>aquaglyceroporins</protein> (<protein>AQP3</protein>, <protein>AQP7</protein>, <protein>AQP9</protein>) with six exons. We conclude that
      <protein>AQP10</protein> represents a new member of <protein>aquaglyceroporins</protein> functionally as well as
      structurally.
</DOC>
<DOC>
<DOC_ID>[63]</DOC_ID>
>63.NF00124514
PMID:12461076
TI  - A signal peptide derived from <protein>hsp60</protein> binds <protein>HLA-E</protein> and interferes with
      <protein>CD94</protein>/<protein>NKG2A</protein> recognition.
AB  - <protein>Human histocompatibility leukocyte antigen (HLA)-E</protein> is a nonclassical <protein>major
      histocompatibility complex (MHC) class I molecule</protein> which presents a
      restricted set of nonameric peptides, derived mainly from the signal
      sequence of other <protein>MHC class I molecules</protein>. It interacts with <protein>CD94/NKG2
      receptors</protein> expressed on the surface of natural killer (NK) cells and T cell
      subsets. Here we demonstrate that <protein>HLA-E</protein> also presents a peptide derived
      from the leader sequence of <protein>human heat shock protein 60 (hsp60)</protein>. This
      peptide gains access to <protein>HLA-E</protein> intracellularly, resulting in up-regulated
      <protein>HLA-E</protein>/<protein>hsp60</protein> signal peptide cell-surface levels on stressed cells. Notably,
      <protein>HLA-E</protein> molecules in complex with the <protein>hsp60</protein> signal peptide are no longer
      recognized by <protein>CD94/NKG2A inhibitory receptors</protein>. Thus, during cellular
      stress an increased proportion of <protein>HLA-E</protein> molecules may bind the
      nonprotective <protein>hsp60</protein> signal peptide, leading to a reduced capacity to
      inhibit a major NK cell population. Such stress induced peptide
      interference would gradually uncouple <protein>CD94</protein>/<protein>NKG2A</protein> inhibitory recognition
      and provide a mechanism for NK cells to detect stressed cells in a
      peptide-dependent manner.
</DOC>
<DOC>
<DOC_ID>[64]</DOC_ID>
>64.NF00116173
PMID:11741979
TI  - Interaction of the C-terminal domain of <protein>p43</protein> and the <protein>alpha subunit of ATP
      synthase</protein>. Its functional implication in endothelial cell proliferation.
AB  - <long_form>Human <protein>p43</protein></long_form> is associated with <protein>macromolecular tRNA synthase complex</protein> and
      known as a <protein>precursor of endothelial monocyte-activating polypeptide II
      (EMAP II)</protein>. Interestingly, <protein>p43</protein> is also secreted to induce proinflammatory
      genes. Although <protein>p43</protein> itself seems to be a <protein>cytokine</protein> working at physiological
      conditions, most of the functional studies have been obtained with its
      C-terminal equivalent, <protein>EMAP II</protein>. To gain an insight into the working
      mechanism of <protein>p43</protein>/<protein>EMAP II</protein>, we used <protein>EMAP II</protein> and searched for an interacting
      cell surface molecule. The level of <protein>EMAP II-binding molecule(s)</protein> was
      significantly increased in serum-starved tumor cells. Thus, the <protein>EMAP
      II-binding molecule</protein> was isolated from the membrane of the serum-starved
      CEM cell. The isolated protein was determined to be the <protein>alpha subunit of
      ATP synthase</protein>. The interaction of <protein>EMAP II</protein> and <protein>alpha-ATP synthase</protein> was
      confirmed by enzyme-linked immunosorbent assay and in vitro pull down
      assays and blocked with the antibodies raised against <protein>EMAP II</protein> and
      <protein>alpha-ATP synthase</protein>. The binding of <protein>EMAP II</protein> to the surface of serum-starved
      cells was inhibited in the presence of <protein>soluble alpha-ATP synthase</protein>. <protein>EMAP II</protein>
      inhibited the growth of endothelial cells, and this effect was relieved by
      <protein>soluble alpha-ATP synthase</protein>. <protein>Anti-alpha-ATP synthase antibody</protein> also showed
      an inhibitory effect on the proliferation of endothelial cells mimicking
      the activity of <protein>EMAP II</protein>. These results suggest the potential interaction
      of <protein>p43</protein>/<protein>EMAP II</protein> with <protein>alpha-ATP synthase</protein> and its role in the proliferation
      of endothelial cells.
</DOC>
<DOC>
<DOC_ID>[65]</DOC_ID>
>65.NF00131727
PMID:11823532
TI  - Biological activities of <protein>ecalectin</protein>: a novel <protein>eosinophil-activating factor</protein>.
AB  - <protein>Ecalectin</protein>, produced by Ag-stimulated T lymphocytes, is a potent
      <protein>eosinophil-specific chemoattractant</protein> in vitro as well as in vivo and thus
      is implicated in allergic responses. <protein>Ecalectin</protein> differs structurally from
      other known <protein>eosinophil chemoattractants (ECAs)</protein>; <protein>ecalectin</protein> belongs to the
      <protein>galectin</protein> family defined by their affinity for beta-galactosides and by
      their conserved carbohydrate recognition domains. These characteristic
      features suggest that <protein>ecalectin</protein> has unique activities associated with
      allergic inflammation besides <protein>ECA</protein> activity. Conversely, <protein>ecalectin</protein> may
      mediate <protein>ECA</protein> activity by binding to a <protein>receptor</protein> of a known <protein>ECA</protein> via affinity
      for the beta-galactosides present on this <protein>receptor</protein>. In this study, we have
      tested whether <protein>ecalectin</protein> mediates <protein>ECA</protein> activity by binding to a <protein>receptor</protein> of
      a known <protein>ECA</protein>, and we have assessed its effects on eosinophils. <protein>Ecalectin</protein>
      did not mediate <protein>ECA</protein> activity by binding to the <protein>IL-5R</protein> or to <protein>CCR3</protein>. Also, the
      <protein>ECA</protein> activity of <protein>ecalectin</protein> was mainly chemokinetic. In addition, <protein>ecalectin</protein>
      induced concentration-dependent eosinophil aggregation, a marker for
      eosinophil activation. <protein>Ecalectin</protein> induced concentration-dependent
      superoxide production from eosinophils but did not induce degranulation;
      usually these two events are coupled in eosinophil activation. Moreover,
      <protein>ecalectin</protein> directly prolonged eosinophil survival in vitro and did not
      trigger eosinophils to secrete <protein>cytokines</protein> that prolong eosinophil survival.
      These results demonstrate that <protein>ecalectin</protein> has several unique effects on
      eosinophils. Therefore, we conclude that <protein>ecalectin</protein> is a novel
      <protein>eosinophil-activating factor</protein>. Presumably, these effects allow <protein>ecalectin</protein> to
      play a distinctive role in allergic inflammation.
</DOC>
<DOC>
<DOC_ID>[66]</DOC_ID>
>66.NF00105565
PMID:11956185
TI  - Transcriptional control of the <long_form>human <protein>thromboxane synthase</protein></long_form> gene in vivo and
      in vitro.
AB  - <protein>Thromboxane A(2)</protein>, a potent mediator of vasoconstriction and platelet
      aggregation, is synthesized from prostaglandin H(2) by <protein>thromboxane
      synthase (TXAS)</protein>. We report here on promoter analyses of <long_form>human <protein>TXAS</protein></long_form> using
      in vitro transcription and in vivo transfection methods. The 39-bp core
      promoter, containing both TATA and initiator elements, accurately
      initiates transcription in an orientation-dependent manner in a cell-free
      transcription system. Mutation of either TATA or initiator abolished
      transcriptional activity, but the upstream sequence had no effect on <protein>TXAS</protein>
      promoter activities in vitro, suggesting that the core promoter is
      sufficient for transcriptional activity from a naked DNA template. In
      contrast, mutation of both elements